Subject Index

### Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AD</td>
<td>Alzheimer’s disease</td>
</tr>
<tr>
<td>APP</td>
<td>amyloid precursor protein</td>
</tr>
<tr>
<td>DLB</td>
<td>dementia with Lewy bodies</td>
</tr>
<tr>
<td>DTI</td>
<td>diffusion tensor imaging</td>
</tr>
<tr>
<td>FAST</td>
<td>Functional Assessment Staging</td>
</tr>
<tr>
<td>FTD</td>
<td>frontotemporal dementia</td>
</tr>
<tr>
<td>GDS</td>
<td>Global Deterioration Scale</td>
</tr>
<tr>
<td>LBD</td>
<td>Lewy body dementias</td>
</tr>
<tr>
<td>MCI</td>
<td>mild cognitive impairment</td>
</tr>
<tr>
<td>MMSE</td>
<td>Mini Mental State Examination</td>
</tr>
<tr>
<td>MTL</td>
<td>medial temporal lobe</td>
</tr>
<tr>
<td>NAA</td>
<td>N-acetylaspartate</td>
</tr>
<tr>
<td>OCD</td>
<td>obsessive-compulsive disorder</td>
</tr>
<tr>
<td>PDD</td>
<td>Parkinson’s disease dementia</td>
</tr>
<tr>
<td>SSRIs</td>
<td>selective serotonin reuptake inhibitors (SSRIs)</td>
</tr>
</tbody>
</table>

Note: All index entries relate to older people and psychiatric disorders unless otherwise indicated. vs denotes differential diagnosis or comparisons.

### 10/66 Dementia Research Group

- dementia criteria 204–205
- dementia impact 722–723
- dementia prevalence in low-/middle-income countries 720, 721, 722
- South Asia 730
- impact of care in South Asia 731
- physical/mental contribution to disability 722–723

### 14-3-3 protein

- 374

### Abdomen

- examination 119
- abdominal pain, examination 119
- absorption, drugs 55, 537, 679
- abuse, of older people see elder abuse accidents, fatal, bereavement considerations 556
- accommodation (housing), concerns, suicidal behaviour 561
- accommodation (ocular), assessment 120
- Accountable Care Organizations 773
- Accreditation Council for Graduate Medical Education (ACGME)
- review of training program structure 858
- training program requirements 857–858
- ACE see Addenbrooke’s Cognitive Examination (ACE)

### Acupuncture

- memory improvement 405, 407, 738

### Acute stress reaction

- clinical features and causes 761
- differential diagnosis 640, 641–642
- therapy 640–641
- adaptation to functional decline 29
- in successful ageing 71

### ACE inhibitors, lithium interactions

- 581

### Adenoviral vectors

- 336

### Adrenocortical axis

- age-related changes 47

### Adrenopause

- 47

### Adrenergic system

- β-adrenergic receptors
- age-related reduced function 57–58
- antagonists see beta-blockers
- adrenocortical axis, age-related changes 47
- adrenocorticotropic hormone (ACTH) 47
- adrenopause 47

### ADetailing

- management 199
- ADRQL measure 187
- childhood, stages 560
- adult stem cell niche 330, 332
- see also neurogenic stem cell niche
- advance care planning 840–841
- advance decisions to refuse treatment (ADRTs) 841–842
- advanced glycation endproducts (AGE) 271–272
- advance directives 411, 769
- instructional 411
- advanced therapeutic technologies 334–338
- advance patient statements 840
- adverse drug reactions (ADRs) 58
- see also specific drug groups
- advocacy service 852

### Adaptations/aids

- in rehabilitation 811
- used in private psychiatric hospitals 796

### Adaptive plasticity

- 42, 43

### Addenbrooke’s Cognitive Examination (ACE)

- 130–131, 132
- ACE-R 130
- language subtests 131–132
- adenovirus (HAV) 331, 336
- adenohypophysis 45–47
- adenosine, pharmacodynamics 58
- adrenoviral vectors 336
- adjustment, after bereavement 557
- adjustment disorder 510, 642
- classification 642
- clinical features 642
- with depressed mood 459, 566
- diagnostic feature 612
- differential diagnosis, PTSD 641
- stressful life events and 499, 642
- treatment 642
- adjustment reactions, long-term care placement 791–792
- Administration on Aging (AoA) 421, 422
- Admiral Nurse service 9, 811
- α2-adrenoceptor agonist, delirium management 199
- Adenosine 45–47
- Adenovirus 336
- Adrenocortical axis 47
- Adrenopause 47
- ADRQL 187
- Advanced directives 411, 769
- Instructural 411
- Advanced therapeutic technologies 334–338
- Advance patient statements 840
- Adverse drug reactions (ADRs) 58
- See also Specific drug groups
- Advocacy service 852

---

*Principles and Practice of Geriatric Psychiatry, 3rd edn. Edited by Mohammed T. Abou-Saleh, Cornelius Katona and Anand Kumar © 2011 John Wiley & Sons, Ltd*
affective disorders see bipolar disorder; depression; mania; mood disorders

Africa
cognitive impairment 735
dementia mortality 734
dementia prevalence 721, 734
demographics 734
depression prevalence 485, 486, 734
treatment of mental illness 735

age
dementia incidence, Lundby study 222, 223
as dementia risk factor 209, 238, 271
depression aetiology 617–618
AGECAT 174, 175, 617
cross-cultural validity of depression assessment 718
see also GMS-AGECAT
age discrimination 525

ageing 83
biological see biological ageing biomarkers 65
cellular and molecular effect 55
chronological 65
concepts 65
fear of 495
functional see functional ageing
global burden see demographics and ageing

‘intrinsic’/‘extrinsic’ factors affecting AD risk 271

normal see normal ageing
as physiological dynamic process 36
plasticity 65
statistics see demographics and ageing
successful see successful ageing
variability 65
whole of life approach 561

ageing biology
human syndromes elucidating 51–52
lower organism evidence 52–53

ageing theories
biological 51–52
medical model 61

ageism 565

age-related cognitive decline 209, 342
dementia vs 201, 209
tau tangles 259
see also normal ageing

aggressive behaviour 553

Alzheimer’s disease 229
during assistance with personal care 761, 762
benzodiazepines causing 627
in care homes 697
dementia 229, 695
forensic history-taking 112
management in NHS continuing care 762
see also behavioural disturbances

agitation
Alzheimer’s disease 229, 312
benzodiazepines causing 627
depression with dementia 553
management in ICU 199
see also delirium

agnosia, Alzheimer’s disease 227
agonists, drug 57
akathisia 702
albumin, drug binding 56, 679
alcohol
abstinence 667
age-related use decline 672, 674
benzodiazepine interactions 627, 682
cognitive performance and 676
daily amounts drunk 673
disability risk with 676
drug interactions 627, 665, 671, 680
effects in elderly 665–666, 671–672
heavy consumption see alcohol abuse, heavy drinking
increased sensitivity in elderly 665–666, 675
light to moderate consumption 666, 667, 674
advantages, nutritional 826
neurotoxicity mechanism 378
outcomes associated with use 675–676
prevalence of use 672, 679
recommended limits 672
tolerance to 666
use in depression 675
vulnerability to toxicity of 665, 671

alcohol abuse 665–670
by abusers of elderly people 836
age/time of onset 666, 674
assessment and screening 667, 673–674
benzodiazepine misuse with 681
causes/stressors 666, 674
criminal presentation 665, 666
crime associated 695
cultural aspects 668
definition of excessive drinking 673
detection/recognition 666–667, 673–674
failure to diagnose, reasons 673
detrimental effects 665–666, 671–672
DSM-IV 671
early-onset 666, 674
epidemiology 671–678
factors contributing to 666, 674
gender differences 672, 674
heavy drinking
factors associated 674
physical impairment 675
prevalence 672–673, 674
increased sensitivity in elderly 665–666, 671
late-onset 665, 666, 674
long-term remission 676
long-term solvent abuse synergism 380
loss of control in use 666
medical/geriatric admissions due to 673, 675
mild cognitive impairment 378, 379, 665
mood disorders due to 566, 675
mortality 666, 675
onset 666, 674–675
outcomes 675–676
paranoid delirium 600
physical conditions associated 665, 667, 675

prevalence 671–672

decline in use with age 672, 674
psychiatric co-morbidity 675
in psychiatric history-taking 111–112
rehabilitation 667
social decline 666–667
suicidal behaviour 560
thiamine deficiency synergistic action 379
treatment 667–668, 683
alcohol-deterring medication 668
withdrawal management 667
symptoms 666
alcohol dependence 666
alcoholic dementia 378–380
neuropathogenesis 378
Alcoholics Anonymous 668, 683, 801
alcohol misuse see alcohol abuse

Alcohol Use Disorders Identification Test (AUDIT) 667

allostasis 47
alstatic load 47
alpha-2 adrenergic agonist, delirium management 199

alpha rhythms in AD 38
decrease in ageing 38
in MCI 39

ALPHA study 213, 214
alpha synucleinopathies see Lewy body dementia spectrum
alprazolam 626

Alzheimer’s Association (AA) 422, 424
Alzheimer’s Caregiver Support Online 422, 424

Alzheimer’s disease (AD)
acupuncture effect 405
Addenbrooke’s Cognitive Assessment 131
advanced see Alzheimer’s disease (AD), severe
daetiology 723–724
affective disturbances 227–228
see also depression (geriatric) aggression 229
agitation 229, 312
amyloid-related synaptic dysfunction before neuron loss 437
anaesthetics effect 821
antemortem markers 299–303
brain imaging 301
genomics and proteomics 301–302
neurochemistry and neurotransmitters 299–300
systemic pathology 300–301
apathetic syndrome (apathy) 230, 308
APOE ε4 gene, risk with 210, 240, 723
see also apolipoprotein E allele e4 (APOE4)
apetite dysregulation 228–229, 826
atherosclerosis and 723
at-risk patients, AD-like functional patterns 29
autosomal dominant 240–244
behavioural disturbances 228, 229, 295, 312, 324
Alzheimer’s disease (AD) continued
management see behavioural management, in AD
see also under dementia;
neuropsychiatric symptoms (non-cognitive)
biomarkers 205, 299–303
brain functional changes 29–30
brain regions affected 29
burden in China 737
burden on elderly caregivers 557
see also family caregivers, stress
caregivers see caregivers/carers; family caregivers
cholinergic deficit 295, 299, 304, 703, 821–822
classification 238
DSM-IV 107
DSM-IV-TR 201
ICD-10 106
clinical features 226–231, 238
affective features 227–228, 324
behavioural problems 229, 324
neuropsychiatric symptoms 226–227
non-cognitive (non-cognitive)
death, causes 238
cumulative lifetime risk 246
EEG changes 38, 126
environmental factors 301, 723
epidemiology 208, 238
Lundby prevalence rates 222, 223
probability of contracting 222
race and gender affecting 246
see also Alzheimer’s disease (AD), prevalence
early stages
Clinical Dementia Rating (CDR) 172
exercise benefits 407
Global Deterioration Scale (GDS) 163, 164–166
memory impairment 226
early-onset familial (EOAD) 238
early-onset (EOAD) vs late-onset (LOAD)
cortical mapping 264
FDG-PET patterns 259
see also Alzheimer’s disease (AD), prevalence
executive dysfunction 227, 239
executive dysfunction syndrome in 230
falls in 230, 763
familial (FAD) 252
molecular neuropathology 287–290
neurogenesis regulation 291
PS1 mutants 292
family history 238, 246
GDS/FAST and CDR scales 163, 166, 167
genes
APP gene mutations 127, 210, 240–242
location and inheritance 240
mutations 29, 127, 240–244
presenilin mutations 127, 210, 242–244
see also amyloid precursor protein (APP); apolipoprotein E allele ε4 (APOE4); presenilin 1; presenilin 2
genetics 51, 209–210, 238–251, 293, 301, 723
AD1 locus (APP) 240–242
AD2 locus (APP) 244–245
AD3 locus (PSEN1) 242
AD4 locus (PSEN2) 242–244
autosomal dominant disease 240–244
see also amyloid precursor protein (APP); apolipoprotein E (APOE); presenilin 1 (PSEN1); presenilin 2 (PSEN2)
genetic testing and counselling 245–246
neiromics 301–302
hallucinations see hallucinations
neuroeconomics, drug interventions 92
heterogeneity of 226
hippocampal neurogenesis 334
historical aspects 4–5
imaging
functional MRI studies 439–440
magnetic resonance spectroscopy 450–451
magnetoencephalography (MEG) 38–39
imaging (metabolic/molecular) 262
see [11C]PIB-PET 259
[18F]FDNNP-PET 259–260, 264, 265
FDG-PET 258–259
PET 258, 262
SPECT 257–258
incidence 238, 415
inflammatory response 300–301
insight reduced 228
language deficits 226–227, 393
late-onset (LOAD) 127, 238, 240, 246
FDG-PET patterns 259
genetics and risk factors 293
‘Leyw body variant’ 360
life expectancy 226, 838
lithium, neuroprotective action 583
long-term care 793
magnetoencephalography (MEG) changes 38–39
melatonin 300, 703
memory deficits 17, 204, 226, 393
mild, cholinesterase inhibitor initiation 306–307
molecular neuropathology 287–290, 287–294
APP 287–289
Aβ misfolding and oligomerization 290–291
calcium homeostasis disturbance 292
in familial AD 287–293
neurogenesis impairment 291
oxidative stress 292–293, 308
presenilins and γ-secretase 289
α-secretase 290
β-secretase 289–290
in sporadic late-onset AD 293
tau hyperphosphorylation 291
see also amyloid beta (Aβ); amyloid precursor protein (APP); secretases, APP cleavage
mortality rate 226
motor cortex organization 37
mouse models see mouse models
neurochemistry see neurochemistry
neuroimaging 301
neuronal loss
Functional Assessment Staging (FAST) 166, 167
nucleus of Meynert 295
neuropsychiatric symptoms see neuropsychiatric symptoms (non-cognitive)
neuropsychological assessment see neuropsychological assessment
neuroimaging pathology 300–301
praxis 227
predictors of progression from MCI 30
prevalence 226, 238, 415, 719, 720
China 737
South Asia 730
SUBJECT INDEX

USA 415, 421
prevention 205
prevention strategies 274–276, 723–724
diet and nutritional supplements 275
Ginkgo biloba 404
lifestyle factors 275–276
pharmacological 274–275
‘probable’ diagnosis 383
progression 226
[18F]FDDNP-PET 264, 265
progressively lowered stress threshold 324
protein abnormalities 300
see also tau
as a proteinopathy (Aβ) 377
proteomic markers 302
regenerative medicine application 331
proteomic markers 302

severity, A
severity assessment
severity, Aβ level associated 290
sever.' 290
severity assessment
CDR stages 163, 170–173
FAST stages 163, 166, 167
GDS stages 163, 164–166
sleep disturbances 230, 703
sporadic
genes associated 244–245
genetics and risk factors 293
staging see dementia, staging
suicidal behaviour and 560, 561, 806
synaptic plasticity 37
temporal lobe atrophy 266, 267, 268
theories/models 324
time course 163
treatment
alternative therapies/supplements 308–309
behavioural management see
behavioural management, in AD
in Down syndrome 284
effect on brain function 32
future therapies 309
pharmacological 304–311
regenerative medicine 331
see also cholinesterase inhibitors;
memantine
unmet needs model 324, 325
vascular dementia with 203, 208, 345
visuospatial deficits 39, 227, 393
without dementia 205
Alzheimer’s disease and related dementias
(ADRD) see Alzheimer’s disease (AD);
dementia
Alzheimer’s Disease Anti-inflammatory
Prevention Trial (ADAPT) 274
Alzheimer’s Disease Centers (ADCs) 422, 423
Alzheimer’s Disease China 738
Alzheimer’s Disease Cooperative Study
(ADCS) 320, 421, 422, 423
Alzheimer’s Disease Education and Referral
Center (ADERAR) 422, 423
Alzheimer’s Disease International 720, 721, 738
Alzheimer’s Disease Neuroimaging Initiative
(ADNI) 262, 265, 268, 422, 423
Alzheimer’s disease societies (USA) 421–425
development 421
federal agencies 241–424
non-profit agencies 424
other supportive organizations 423, 425
patient and caregiver support
organizations 424–425
role and support from 421
Alzheimer’s Center of America (AFA) 422, 424
Alzheimer’s Reserach & Prevention
Foundation (ARPFF) 422, 424
Alzheimer’s Society (UK) 759, 764, 814
ambulatory psychiatric care 777–784
American Association of Geriatric
Psychiatry (AAGP) 774
American Federation for Aging Research
(AFAR) 423, 425
amiodarone, elimination half-life 57
amitriptyline, depression in Parkinson’s
disease 449
amnesia
complete generalized 643
dissociative 643
organic 643
see also memory impairment/deficits
AmpA Kines 297
amygdala
NAA increase in depression 449
volume reduction, recurrent depression 489
amyloid, cerebrovascular, [11C]PIB-PET
imaging 259
amyloid beta (Aβ) 239, 287
antibodies 253, 291
Aβ40 239, 240, 252, 281, 290
Aβ42 239, 240, 243, 252, 281, 290, 300
increased 241–242, 243
Aβ42 to Aβ40 ratio increased 240, 242, 243, 252, 290
β-sheet structure formation 287
binding to apoE 245
clearance 293
hypertension affecting 272
decreased in CSF, in AD 300
deposition
Alzheimer’s disease 239, 245, 265,
281, 291
Down syndrome 281
neuronal activity relationship 440
role 291
[18F]FDDNP-PET imaging 259
formation from APP see amyloid
precursor protein (APP)
formation prevention by α-secretase 290
glutameric transmission reduction 296
increased levels 287, 290
AD severity association 290
increased reactive oxygen/nitrogen species
due to 292–293
in Lewy body dementias 363
misfolding and oligomerization 290–291
anaesthetic agents causing 821
neurotoxicity prevention by antioxidants
293
role in AD 287–288
transgenic mouse models 252, 254–255,
291
vaccine, withdrawal 309
amyloid cascade hypothesis 252
amyloidosis, transgenic mouse models 252
amyloid beta (Aβ) 252, 254–255
amyloid plaques 218, 287
in Alzheimer’s disease 239
in Down syndrome 281
structure 239
amyloid precursor cleaving enzyme 1, β-site
(BACE1) see BACE1
amyloid precursor-like protein 1 (APLP1) 287, 289
amyloid precursor-like protein 2 (APLP2)
287, 289
amyloid precursor protein (APP) 239,
287–290
Alzheimer’s disease genetics 240–242
APP gene 254
alternative splicing 241
function and expression 240–241
location and structure 240, 241
mapping 240, 241
APP gene mutations 287–288, 301
Alzheimer’s disease 127, 210,
240–242
inheritance and clinical features 240
L723P mutation 241–242
‘London’ mutations 241, 254
missense mutations 240, 241
‘Swedish’ mutations 241, 252, 254, 290
V717I mutation 241
V717F mutation 241
amyloid precursor-like protein 1 (APLP1)
287, 289
amyloid precursor-like protein 2 (APLP2)
287, 289
amyloid precursor protein (APP) 239,
287–290
Alzheimer’s disease genetics 240–242
APP gene 254
alternative splicing 241
function and expression 240–241
location and structure 240, 241
mapping 240, 241
APP gene mutations 287–288, 301
Alzheimer’s disease 127, 210,
240–242
inheritance and clinical features 240
L723P mutation 241–242
‘London’ mutations 241, 254
missense mutations 240, 241
‘Swedish’ mutations 241, 252, 254, 290
V717F mutation 241
in OCD 634
pharmacokinetics 625
starting doses 625
apathy 499
Alzheimer’s disease 230
cholinesterase inhibitor effect 308
depression co-morbid with 228
Down syndrome 283
frontotemporal dementia 348
treatment in depression 470
apex beat, in examination 119
apha 1 genes 289
aphasia 132
apo-noe, sleep 703
apo-noea-hypo-noe index (AHI) 703
apolipoprotein E (APOE) 244–245,
281–282
Alzheimer’s disease risk 240, 244–245,
271, 273
see also apolipoprotein E allele ε4
(APOE4)
binding to aggregated Abβ 245
gene function and expression 244–245
gene location and structure 244, 245
gene testing and counselling 245–246
inheritance and clinical features 244
isofoms modulating lipid level for
neurons 245
late-life depression risk 461
polymorphisms 244, 245, 723
toxicity mechanism 244
apolipoprotein E allele ε2 (APOE2) 244
APOE 2/2 245
dementia incidence 217
dementia protective factor 210, 282
apolipoprotein E allele ε3 (APOE3) 244
APOE 3/3 245
APOE 3/4 245
dementia incidence 217
apolipoprotein E allele ε4 (APOE4) 29,
244, 245–246
AD risk 29, 127, 210, 271, 282, 293,
723
as antemortem marker 301
ever life experience interactions 273
predictive testing for E4 allele 410
risk with one allele 246
South Asia 730
vascular risk factors modified by 272
APOE 4/4 245–246
delirium pathophysiology 197
dementia incidence 217
depression with 567
suicidal behaviour 561
Down syndrome and 282
apoklesis 36
apparent volume of distribution (V) 55–56
APP carboxyl terminus fragments (AICD)
239, 288
appearance in Mental State Examination (MSE) 113
in physical examination 118
appetite dysregulation, Alzheimer’s disease 228–229, 826
apraxia ideational, Alzheimer’s disease 227
ideomotor, Alzheimer’s disease 227
Area Agencies on Aging (AAA) 424
Area Health Authorities 746
arginine-vasopressin (AVP)
age-related changes 48
inappropriate secretion 538
receptors 48
aripiprazole Alzheimer’s disease 314
bipolar disorder 582
dosage and adverse effects 313
effect on brain function 32
partial agonist at D2 receptors 57
in treatment-resistant depression 540
arrest, elderly offenders 696
arson 695
arterial spin label (ASL) imaging 435, 438
arteriosclerosis, historical aspects 4
cerebrovascular disease 344
artificial neural networks (ANNs) 39
Asia
depression incidence 486
depression prevalence 482–483,
483–485
see also East Asia; South Asia
Asians, in UK see South Asians (in UK)
Asp see BACE1
Asperger’s syndrome 696
assessment of mental health
ethnic groups 713
see also neuropsychological assessment
assisted living facilities, in US 790
Association for Frontotemporal Dementias (AFTD) 422, 424
asylums 745
atheroma, subclinical, vascular disease and
depression 470
atherosclerosis 272, 723
tropic, premedication before ECT 532
attention 195
alternating, testing 390
assessment 131, 138, 389–390, 391
confounding factors 390
deficits/impairment 137
in Lewy body dementias 364–365
delirium diagnosis 195
divided, testing 390
selective
Down syndrome 283
testing 389
simple span, testing 389
attributable fraction (AF) 847
audit, NHS continuing care 760
AUDIT (Alcohol Use Disorders Identification Test) 667
auditory hallucinations 114
incidence/prevalences 597
Lewy body dementias 365
auditory problems, management in AD 327
auscultation, in examination 119
Australia
depression prevalence 485
malnutrition prevalence 824
autoantibodies 124
autobiographical history 130
autoimmune diseases, investigations 124
Automated Geriatric Examination for
Computer Assisted Taxonomy (AGECAT) see AGE CAT
autonomic dysfunction
depression and vascular disease 469–470
Lewy body dementias 365
autonomy 766
autoregulation, hippocampus CA1
neuronal loss 260
Axis I and II disorders see under DSM-IV
axonal transport, impairment in AD 291
Ayurveda 405–406, 407
Ayurvedic medicines 405
Babinski sign, assessment 121
‘baby boomers’ 83, 770, 857
BACE1 254, 289–290
APP cleavage 289
expression 289
increased in AD 290
inhibition by native prion protein 377
knock-out mice 254, 290
regulators 290
synthesis and transport 290
BACE2 290
backward-digit span 131
Balanced Budget Act (BBA-97) (1997) 771
Bali’s syndrome 132
Baltimore Longitudinal Study of Ageing 65
barium X-ray tests 124
Barthel Index 180
basal ganglia, in OCD 633
BASDEC scale 142
BDNF see brain-derived neurotrophic factor (BDNF)
Beck Depression Inventory (BDI) 142, 569
Beck Depression Inventory II (BDI-II) 392
bedside assessment, of cognitive functioning see cognitive functioning assessment
Beers criteria 795
Behavioral Rating Inventory of Executive Function - Adult version (BRIEF-A) 392
Behavioral Risk Factor Surveillance System (BRFSS) 673
behaviour
aggressive see aggressive behaviour
changes, cognitive assessment 129–130
context-dependent, personality disorders 637
impaired
Alzheimer’s disease 229, 312
dementia classification 202
see also behavioural disturbances
maladaptive interpersonal, in personality disorders 659
in Mental State Examination (MSE) 113
positive reinforcing 543
rating/rating scales 141
rigidity 129
stabilization, delirium treatment 198
suicidal see suicidal behaviour
behavioural activation 543
behavioural and psychological symptoms (BPSD) see dementia, behavioural and psychological symptoms (BPSD)
behavioural disorders
DSM-IV 107
ICD-10 106
behavioural disturbances
Alzheimer’s disease 228, 229, 295, 312
effect on caregivers 417, 830, 832
management see behavioural management, in AD
theories underlying 324
in care homes 78
dementia 210–211, 216
impact on caregivers 830
in offenders 696
in depression 498
FTD syndromes 348, 353
management see behavioural management medical/neurological disorders 426–432
cryptococcosis 428–429, 430
herpes simplex encephalitis 429, 431
Lyme disease 427–428
neurophilis 428
tuberculosis 426–427
relocation to institutions 832
see also neuropsychiatric symptoms (non-cognitive)
behavioural factors, depression and vascular disease link 470
behavioural management
non-pharmacological
in AD see behavioural management, in AD
in FTD syndromes 353
in Lewy body dementias 367
pharmacological
in AD see behavioural management, in AD
in Lewy body dementias 368
behavioural management, in AD 312–323
non-pharmacological 324–329
for affective symptoms 325–326
for behavioural symptoms 325
cognitive interventions 326
efficacy 327
funding issues 327
to improve function 326
individualization 327
prerequisites and barriers to 327
staff training 325
theoretical frameworks for 324
pharmacological
antipsychotic drugs 319
anxiolytics 313–318
approach to 313
assessment and initiation 320
cholinesterase inhibitors 318–319
funding and prescribing 327
general principles 320
memantine 319
monitoring 320
mood stabilizers 320
other drugs 320
outcomes and goals 320
see also individual drug groups
behavioural model (in AD) 324
behavioural therapy
drug misuse 683
insomnia 701
multi-sensory 798
obsessive–compulsive disorder 633
see also cognitive behavioural therapy (CBT)
Behaviour Rating Scale 142
benzodiazepine agonists, insomnia treatment 701
benzodiazepines 625–627
abuse, dementia associated 380
in acute stress reaction 640
in alcohol withdrawal 667
anxiolytic 625, 626
chronic/long-term use 680, 683
delirium controlled by in ECT 533
delirium induced/worsened by 198
development 626, 683
psychiatric history-taking 111–112
drug interactions 626, 627
efficacy in anxiety 626
increased sensitivity to 58
indications 680
South Asia 731
institutional use 680
long half-life 626
metabolism 626, 627
misuse 680–681
alcohol abuse with 681, 682
detection 682
gender and age 681
late-onset 681
treatment 683
OBRA Interpretive Guidelines 794
pharmacokinetics 625–626
prevalence of use 680
psychiatric morbidity with 681
sedative-hypnotics 625, 626
selection, criteria 627
short to intermediate half-life 626, 627
side effects 626–627, 642, 667
ultra-short half-life 626
withdrawal 626, 683
bereavement 459, 555–558
acute stress reaction due to 640
animal companion’s death 557
child/grandchild’s death 555
concerns after 555
early phases 556–557
later phases 557–558
pre-bereavement situation 555–556
PTSD after 641
spousal 498, 499, 555, 556
cause of depression 520
as status marker, and new roles 557
at time of death 556
see also grief
bereavement overload 557
‘best interests’ 853
best interest standard 411
beta-amyloid see amyloid beta (Aβ)
beta-blockers
anxiety/anxiety disorders 628–629
PTSD 642
β-sheets 287, 372
Bethlem Hospital 12
psychiatric geriatric unit 7, 12, 13
Beveridge Report 746
biochemistry, investigations 123–124, 345
biofeedback, memory training 406, 407
biological age, offenders, needs assessment 694
biological ageing 61
quantification 60
biological risk factors, as anxiety risk factor 620
biomarkers
of ageing, criteria for 65
Alzheimer’s disease 205, 299–303
treatment benefit identification 309
see also Alzheimer’s disease, antemortem markers
dementia diagnosis, impact on epidemiology studies 211
frontotemporal dementia 350–351
Lewy body dementias 366–367
biomedical theories, successful ageing 71, 72
bipolar disorder 500, 576–588
age of onset 573, 576–577
‘burn-out’ 576
classification 458
clinical features and health service usage 579
cognitive impairment 578–579
community vs hospital prevalence 576
course 577
definition/description 576
depression as first episode 573, 577
diagnosis, clinical implications 579
early-onset 576–577, 579
epidemiology 576
euthymic 579
functional impairment association 178
genetics/family history 577
history-taking and investigations 580
late-onset 460, 573, 576–577, 579
 genetics 461
magnetic resonance spectroscopy 449, 450
management 580–583
acute mania treatment 580–582
adherence/compliance 583
APA guidelines 582
challenges in and lack of trials 580
drug therapy 582
maintenance therapy 583
psychotherapy 583
manual-based medical care model 583
mortality 576
neuroimaging 578
outcome, relapse and hospitalization 577
psychiatric/medical co-morbidity 577–578, 583
rapid cycling, valproate therapy 581
refractory, management 540
stressful life events and 579
suicidal behaviour 560
<table>
<thead>
<tr>
<th>SUBJECT INDEX</th>
</tr>
</thead>
<tbody>
<tr>
<td>switch from unipolar depression 577</td>
</tr>
<tr>
<td>treatment 539</td>
</tr>
<tr>
<td>vascular subtype 578, 579</td>
</tr>
<tr>
<td>see also depression (geriatric); mania</td>
</tr>
<tr>
<td>bipolar disorder medical care model (BCM)</td>
</tr>
<tr>
<td>biopsy II disorder 458, 497</td>
</tr>
<tr>
<td>Birren, James 60, 61</td>
</tr>
<tr>
<td>birth cohort differences, depression aetiology 618</td>
</tr>
<tr>
<td>bismuth encephalopathy 380</td>
</tr>
<tr>
<td>black Caribbean people (UK), depression attitudes to seeking help for 520, 521</td>
</tr>
<tr>
<td>barriers to care for 518, 522</td>
</tr>
<tr>
<td>concepts and causation of 520</td>
</tr>
<tr>
<td>facilitators to care 519–520</td>
</tr>
<tr>
<td>Blessed Dementia Scale 170</td>
</tr>
<tr>
<td>Bleuler, Manfred 592</td>
</tr>
<tr>
<td>blood flow, changes, functional imaging 28</td>
</tr>
<tr>
<td>blood mononuclear cells (BMCs), genomics, AD antemortem marker 302</td>
</tr>
<tr>
<td>blood pressure</td>
</tr>
<tr>
<td>depression relationship 468</td>
</tr>
<tr>
<td>in examination 119</td>
</tr>
<tr>
<td>high see hypertension</td>
</tr>
<tr>
<td>low, postoperative cognitive dysfunction 818, 820</td>
</tr>
<tr>
<td>low diastolic</td>
</tr>
<tr>
<td>AD risk relationship 272</td>
</tr>
<tr>
<td>depression relationship 468</td>
</tr>
<tr>
<td>white matter lesion risk 344</td>
</tr>
<tr>
<td>body mass index (BMI) 273, 825</td>
</tr>
<tr>
<td>sleep-disordered breathing 703</td>
</tr>
<tr>
<td>body shape changes, sexuality and 707</td>
</tr>
<tr>
<td>body size, cellularity relationship, decreased life span 52</td>
</tr>
<tr>
<td>BOLD fMRI 28, 437–438</td>
</tr>
<tr>
<td>in older people 435</td>
</tr>
<tr>
<td>perfusion MRI as alternative 435</td>
</tr>
<tr>
<td>as relative measure, and statistics 438</td>
</tr>
<tr>
<td>bondage, postmortem 695</td>
</tr>
<tr>
<td>bootstrapping 92, 93, 94</td>
</tr>
<tr>
<td>borderline personality disorder (BPD)</td>
</tr>
<tr>
<td>ageing affecting 656</td>
</tr>
<tr>
<td>cognitive distortions 650</td>
</tr>
<tr>
<td>treatment, psychotherapy 658, 659</td>
</tr>
<tr>
<td>Borrelia burgdorferi (Lyme disease)</td>
</tr>
<tr>
<td>427–428</td>
</tr>
<tr>
<td>Boston Diagnostic Aphasia Exam 391</td>
</tr>
<tr>
<td>Boston Naming Test 391</td>
</tr>
<tr>
<td>bovine spongiform encephalopathy (BSE) 373, 375, 376</td>
</tr>
<tr>
<td>Braak staging 295</td>
</tr>
<tr>
<td>bradykinesia 133</td>
</tr>
<tr>
<td>brain atrophy 36</td>
</tr>
<tr>
<td>alcoholic dementia 378–379</td>
</tr>
<tr>
<td>bipolar disorder 578</td>
</tr>
<tr>
<td>brain-derived neurotrophic factor (BDNF) 42, 337</td>
</tr>
<tr>
<td>depression aetiology and 619</td>
</tr>
<tr>
<td>Brain Fitness programme 398</td>
</tr>
<tr>
<td>‘brain games’ 400</td>
</tr>
<tr>
<td>brain imaging</td>
</tr>
<tr>
<td>vascular dementia 345</td>
</tr>
<tr>
<td>white matter lesions 344, 490–491</td>
</tr>
<tr>
<td>see also neuroimaging</td>
</tr>
<tr>
<td>brain injury, AD risk 272</td>
</tr>
<tr>
<td>brain mapping 29</td>
</tr>
<tr>
<td>3D, in depression 490</td>
</tr>
<tr>
<td>brain metabolites see myo-inositol</td>
</tr>
<tr>
<td>brain sclerosis see arteriosclerosis</td>
</tr>
<tr>
<td>brainstem respiratory neurons, degeneration 703</td>
</tr>
<tr>
<td>brain tumours, malignant, reversible dementia 386</td>
</tr>
<tr>
<td>brain volume changes with age, fMRI studies 435</td>
</tr>
<tr>
<td>reduced in Down syndrome 283</td>
</tr>
<tr>
<td>breathing disorders, sleep-related 703</td>
</tr>
<tr>
<td>brief alcohol counselling (BAC) 667</td>
</tr>
<tr>
<td>Brief Cognitive Rating Scale (BCRS) 166</td>
</tr>
<tr>
<td>Brief Psychiatric Rating Scale (BPRS) 312, 313</td>
</tr>
<tr>
<td>brief psychotherapy</td>
</tr>
<tr>
<td>acute stress reaction 641</td>
</tr>
<tr>
<td>adjustment disorder 642</td>
</tr>
<tr>
<td>personality disorders 658</td>
</tr>
<tr>
<td>Bristol Activities of Daily Living Scale (BADL) 811</td>
</tr>
<tr>
<td>Broadmoor high security hospital 697</td>
</tr>
<tr>
<td>Buffon, M. Le Comte 3</td>
</tr>
<tr>
<td>burden of care, dementia see care, burden of buspirone 57, 627</td>
</tr>
<tr>
<td>efficacy and administration 627</td>
</tr>
<tr>
<td>in OCD 634</td>
</tr>
<tr>
<td>side effects 627</td>
</tr>
<tr>
<td>Butler Hospital (Rhode Island, USA) 799, 800</td>
</tr>
<tr>
<td>discharge diagnosis 800</td>
</tr>
<tr>
<td>partial hospital programme 800</td>
</tr>
<tr>
<td>butyrylcholinesterase 305–306</td>
</tr>
<tr>
<td>reversible inhibitor 305</td>
</tr>
<tr>
<td>see also cholinesterase inhibitors; rivastigmine</td>
</tr>
<tr>
<td>CADDASIL, genetic testingHuntington’s disease 127</td>
</tr>
<tr>
<td>Caenorhabditis elegans</td>
</tr>
<tr>
<td>ageing, and genetics 52, 53</td>
</tr>
<tr>
<td>presenilins and γ-secretase 289</td>
</tr>
<tr>
<td>caffeine, before ECT 532</td>
</tr>
<tr>
<td>CAGE screen 667, 673</td>
</tr>
<tr>
<td>calcipressin 282</td>
</tr>
<tr>
<td>calcium ions delirium pathophysiology 197</td>
</tr>
<tr>
<td>homeostasis defects in AD 292</td>
</tr>
<tr>
<td>calcium phosphate, accumulation 4 calculations, assessment 132</td>
</tr>
<tr>
<td>colonic intake restriction 53–54, 65</td>
</tr>
<tr>
<td>Cambridge ACE test 132</td>
</tr>
<tr>
<td>Cambridge Neuropsychological Tests Automated Battery (CANTAB) 392</td>
</tr>
<tr>
<td>CAMCOG, in CFAS I/II study 216</td>
</tr>
<tr>
<td>CAMDEX-DS 284</td>
</tr>
<tr>
<td>Canadian Academy of Geriatric Psychiatrists 861</td>
</tr>
<tr>
<td>Canadian Study of Health and Aging 675, 676</td>
</tr>
<tr>
<td>cancers, in learning disability 691</td>
</tr>
<tr>
<td>CANTAB 392</td>
</tr>
<tr>
<td>capacity see mental capacity Capacity Act (2005) see Mental Capacity Act (2005)</td>
</tr>
<tr>
<td>cariprazine syndrome 229, 312</td>
</tr>
<tr>
<td>carbamazepine</td>
</tr>
<tr>
<td>acute mania 581</td>
</tr>
<tr>
<td>Alzheimer’s disease 320</td>
</tr>
<tr>
<td>monitoring 126</td>
</tr>
<tr>
<td>carbohydrate craving 348</td>
</tr>
<tr>
<td>cardiac side-effects, psychotropic drugs 125, 126</td>
</tr>
<tr>
<td>cardiac surgery, anaesthesia effect on cognitive decline 820, 821, 822</td>
</tr>
<tr>
<td>cardiovascular disease</td>
</tr>
<tr>
<td>alcohol use and 675</td>
</tr>
<tr>
<td>dementia aetiology and 210, 723</td>
</tr>
<tr>
<td>depression association 509</td>
</tr>
<tr>
<td>see also heart disease</td>
</tr>
<tr>
<td>cardiovascular system</td>
</tr>
<tr>
<td>dementia risk factor 210, 723</td>
</tr>
<tr>
<td>depression and mortality and 619</td>
</tr>
<tr>
<td>ECT risk factors 531</td>
</tr>
<tr>
<td>examination 118–119</td>
</tr>
<tr>
<td>care</td>
</tr>
<tr>
<td>burden of dementia 66, 557, 731</td>
</tr>
<tr>
<td>palliative care and 839</td>
</tr>
<tr>
<td>see also caregivers/carers</td>
</tr>
<tr>
<td>meanings of term 749, 767</td>
</tr>
<tr>
<td>see also caregivers/carers; community care; day care/services; long-term care</td>
</tr>
<tr>
<td>care arrangements, South Asia 731–732</td>
</tr>
<tr>
<td>caregivers/carers</td>
</tr>
<tr>
<td>Alzheimer’s disease</td>
</tr>
<tr>
<td>non-pharmacological interventions by 327</td>
</tr>
<tr>
<td>training, for behavioural interventions 325</td>
</tr>
<tr>
<td>communication with, long-term care in US 791, 792</td>
</tr>
<tr>
<td>condoning alcohol misuse 682</td>
</tr>
<tr>
<td>dementia patients</td>
</tr>
<tr>
<td>care burden 66, 557, 731</td>
</tr>
<tr>
<td>day hospital benefits 754, 755</td>
</tr>
<tr>
<td>spirituality and 742</td>
</tr>
<tr>
<td>stress in 731</td>
</tr>
<tr>
<td>support for 9</td>
</tr>
<tr>
<td>dementia vs non-dementia 830</td>
</tr>
<tr>
<td>different cultures 714</td>
</tr>
<tr>
<td>elder abuse by 836</td>
</tr>
<tr>
<td>elderly, health status 556</td>
</tr>
<tr>
<td>to elderly people with learning disability 692</td>
</tr>
<tr>
<td>family see family caregivers</td>
</tr>
<tr>
<td>impact of caring on 731, 756, 791</td>
</tr>
<tr>
<td>as imposters, delusions 326</td>
</tr>
<tr>
<td>needs, rehabilitation and 811 numbers, population demographics and 84</td>
</tr>
<tr>
<td>people acting as 829</td>
</tr>
<tr>
<td>pre-bereavement situation 556</td>
</tr>
<tr>
<td>public policy and cost implications 829 at risk of physical abuse 835</td>
</tr>
<tr>
<td>role in rehabilitation 811</td>
</tr>
<tr>
<td>selective prevention of mental disorders 845</td>
</tr>
<tr>
<td>spiritual support for patients 742, 743 stress 415–416, 417, 731</td>
</tr>
</tbody>
</table>
Clinical Dementia Rating (CDR) 164, 165, 170–173
neuropsychiatric effects 307–308, 318–319
non-responders 306
as part of rehabilitation 814
prescribing and monitoring 306–307 rationale for 304
selection/choice 307
side effects 304–305, 314
switching 306
vascular dementia 345
see also acetylcholinesterase inhibitors; donepezil; galantamine; rivastigmine
chronic care facilities (CDR-CC) 172
Chronic Illness
chronic care facilities (CDR-CC) 172
Chronic fatigue syndrome 644
see also neurasthenia
chronic illness
increase in and concerns over 183
prevention of mental disorders in 845
spirituality and 741
see also physical illnesses
chronic obstructive pulmonary disease (COPD) 806
chronic wasting disease (CWD) 376
chronological ageing 65
circumlocution, Alzheimer’s disease 393
cirrhosis 379, 672
citalopram
Alzheimer’s disease 319
anxiety/obsessive disorders 628
depression 539
depression in Parkinson’s disease 475
classification see entries beginning DSM or ICD: specific disorders
Clinical Dementia Rating (CDR) 164, 165, 170–173
AD8 scores 172
adaptations 172
CDR-SB 171
characteristics 171–172
cholinergic deficit in moderate/severe AD 295
chronic care facilities (CDR-CC) 172
development 170
Driving in dementia, decision 412
early stages of dementia 165, 172
GDS comparison 165
global scale 170
interview 170, 172
multi-axial staging 166
overview 170–171
potential limitations 172
scale and details 163, 171
scoring 165, 170
semi-structured interview with informant 170, 172
stability over time 172
time course of changes (normal to AD) 163
validity and reliability 170, 172
clinical governance 747
Clinical Institute Withdrawal Assessment Scale for Alcohol (CIWA-Ar) 667
clinical neuropsychological assessment 135
see also under neuropsychological assessment
clinical neuropsychology 232
role 233
clinical trials, regenerative medicine, design 337
clinicians see general practitioners (GPs); psychotherapists
Clock Drawing Test 392
clozapine, OCD treatment 633
Clock Daylight Test 392
clozapine, OCD treatment 633
clanzepam 626
REM sleep behaviour disorder 702
Clozapine
acute mania 581
cardiac effects 125
Lewy body dementias 369
monitoring 126–127
psychotic disorders 605
Cockayne syndrome type 1 (CS) 52
Cockroft–Gault (CG) equation 56, 57
cognition/cognitive abilities
age-related changes 60–64, 66, 392–393
brain locations and specific abilities 62
fluid vs crystallized abilities 62
‘general slowing theory’ 61
normal vs abnormal 137, 209, 392–394
quantitation 61
response times association 61
sensory changes affecting 60
study methodologies 62
terminal decline 61
testing for see neuropsychological assessment
alcohol use and 676
assessment see cognitive functioning assessment
assessment scales 115
in behavioural variant FTD 348–349
Down syndrome and 283
dysfunctional see cognitive decline; cognitive impairment
fluctuations, in Lewy body dementias 365
lifelong optimal level, prediction 138
Mental State Examination (MSE) 115
pre-existing, in Down syndrome, AD and 283
profiles in ageing conditions 392–394
cognitive behavioural therapy (CBT) 543–544
case example 544–545
‘Coping with Depression’ (CWD) course 846
depression management in Parkinson’s disease 474–475
prevention 846, 847
dysthymia 549
efficacy 546
indicated prevention of depression 846
insomnia management 701
internet-based 846
‘medically unexplained symptoms’ 639
in OCD 633
psychotic disorder management 605–606
outcome 606
in somatoform disorders 638
cognitive decline
definition 342
Down syndrome 283
normal ageing 392–393
profiles in ageing conditions 392–394
progressive, in AD 226
white matter lesions (WMLs) 344
see also cognitive impairment
cognitive deficits see cognitive impairment
cognitive disorders
classification 105–108
with many causes, dementia as 204
cognitive distortions 650
in personality disorders 650
cognitive domains, evaluation 389–392
see also neuropsychological assessment
cognitive dysfunction, postoperative see postoperative cognitive dysfunction (POCD)
cognitive enhancement
educational training see cognitive training
drugs see cholinesterase inhibitors
memory training see memory training
neurofeedback 406
types 397
cognitive enhancers see cholinesterase inhibitors; memantine
Cognitive Function and Ageing Studies (CFAS) 213–221, 480
aims 213–214
CFAS I as resource 216–217
screening interview 216
study population 215–216
CFAS II as resource 216–217
screening interview 216
study population 216
dementia risk factors 216, 217
Funding from MRC 213
methodology 214–215
test 216
interview method 216
SUBJECT INDEX 873
Cognitive Function and Ageing Studies (CFAS) continued
study population 215–216
neuropathological factors in dementia 218
prevalence/incidence of dementia 216, 217
selected findings 216
study design 213, 215
cognitive functioning assessment 137, 390, 391
cognitive gerontology 60–64
deletion relationship, in Parkinson's day hospitals role 754
consent for sexual relations and 75
Alzheimer's disease 226–227
alcohol abuse causing 665, 676
in Africa 735
study design 213, 215
selected findings 216
Alzheimer's disease 233
in Down syndrome 283–284
at bedside 128–134
cognitive domain assessment 131–133, 137
cognitive rating scales 130–131
initial observations 130
neurological examination 133, 137
ethnic groups/cultural differences 715
functional ability prediction and 137
in general hospitals 804
depression with 386, 458, 495, 499, 505, 568–569
depression treatment effect 394
recovery 234–235, 394
treatment of 499
ECT side effect 530
effect on functional abilities 177–178
in FTD 353
functional disability associated 66, 67
Geriatric Depression Scale use in 154
global, dementia as 201, 208
late-onset schizophrenia 598
Lewy body dementia 364–365
management 367–368
in mania 578–579
normal ageing changes vs 137, 209, 392–394
personality disorders vs diseases with 657
postoperative see postoperative cognitive dysfunction (POCD)
progressive, in AD 226
psychotic disorders 593, 606
recovery, in depression 234–235, 394
schizophrenia 593
screening, in general hospitals 804
vascular 342, 343
see also cognitive decline
co-morbidity in older people 117, 122, 141
alcohol abuse 675
bipolar disorder and medical/psychiatric disorders 577–578
depression see depression (geriatric), co-morbidity in Down syndrome 283
inpatient private hospital patients 798
inpatients see medical psychiatric inpatient unit (US)
insomnia and 701
personality disorders 651
see also physical illnesses; specific psychiatric disorders
compensation, for functional decline 29
compensation theory, functional 438–439, 440, 441
competitive antagonism 57
complementary and alternative medicine (CAM) 403–409
exercise 406–407
insomnia treatment 701–702
relaxation, stress reduction and biofeedback 406
trends in use in USA 403
yoga and meditation 406
see also acupuncture
Completion of Training (CCT) 855
compliance problems, psychiatric history-taking 110
Comprehensive Assessment and Referral Evaluation Schedule (CARE) 142
compulsive behaviours 632
compulsory detention
Mental Capacity Act 2005 853
Mental Health Act 1983 851
Mental Health Act 2007 852
Percy Commission 850
computational anatomy, in AD 262–270
cortical maps in MCI vs AD 264
cortical thickness mapping 262–264
definition/description 262
hippocampal radial mapping 268, 269
tensor-based morphometry 265–268
time-lapse maps and trajectory 264–265
computed tomography (CT) 124, 125, 433
Alzheimer’s disease 301
erpes simplex encephalitis 431
principle and technique 433
resolution improvements 433
structural imaging of brain 433
white matter lesions 344
computer-assisted cognitive interventions 398–399
medication with 399
COMT inhibitors, depression in Parkinson's disease 475
confidentiality
different cultures 714
family involvement (US private practice) 781
geneic tests 127
confusion
acute see delirium
chronic see dementia
ECT side effect 529, 532, 533
SUBJECT INDEX

congophilic angiopathy, dementia association 218
Congo Red 821
conjugation, of drugs 56, 626, 627
consciousness, loss, Lewy body dementias 366
consent 411
for ECT 529, 533
for investigations 127
to sexual relations 75
consequences, behavioural model of AD 324
consequentialism 766
consultation, liaison psychiatry 803, 804
continuing professional development (CPD),
old age psychiatrists 855–856
continuous arterial spin labelling (CASL) 435
continuous positive airway pressure (CPAP) 703
continuum of care, private psychiatric hospitals and outpatients 799
Controlled Oral Word Association Task 391
convalescent rehabilitation units 8
conversion disorders 643
classification 642–643
somatoform disorders 642–643
Coolidge Axis II Inventory 651
coordination, assessment 121
coping
after bereavement 555
difficulties 557
with grief 556
personal responsibility for (cross-cultural) 520–521
coping abilities 464–467
definition with age, anxiety and 624
depression prevention 511
diverse/restricted social networks and 466
experience-based 465
interactive (spousal) basis 465
life-span/life-course perspective 464, 465
multigenerational transactions 464
socioeconomic status and ethnicity 465
stress-reducing strategies 465
coping behaviour, negative (smoking, alcohol) 465
coping strategies
dementia patients in care homes 80
depression
ethnic groups 518, 520
religious practices 518
in long-term mental disorders 98
‘Coping with Depression’ (CWD) course 846
copper, levels in AD 301
copy-number variations (CNVs) 460
corneal reflex 120
Cornell Dysthymia Rating Scale 498
Cornell Scale for Depression in Dementia (CSDD) 142, 154
coronary heart disease (CHD) depression and 619
see also myocardial infarction
corpus callosum
axon diameter, DTI 21
quantitative fibre tracking 18, 21
cortical disease 233
cortical excitability 37–38
Alzheimer’s disease 37–38
normal ageing 37
cortical pattern matching (CPM) 262–263
cortical–subcortical distinction 233
cortical syndromes, observation in 130
cortical thickness mapping, Alzheimer’s disease 262–264
corticobasal syndrome (CBS) 349
corticotrophin (ACTH) 47
cortisol, age-related changes 47
costs
Alzheimer’s disease (AD) 271, 312, 421
in USA 421
delirium 826
dementia 207–208, 271, 722
depression and depression treatment 565, 844
direct medical/non-medical 90
discounting 94
family caregivers 829
indirect 90
informal care 91–92
institutional care (UK) 746
medical psychiatric inpatient unit 787
see also expenditure on health; funding;
health economics
cost analysis (CA) 91
cost benefit analysis (CBA) 91
cost consequence analysis (CCA) 91
cost description (CD) approach 90–91
cost-effectiveness, quality of life (QoL) measures 186
cost-effectiveness analysis (CEA) 91, 94
ethics 95
cost minimization analysis (CMA) 91
cost of illness (COI) 91
mental disorders in Europe 92
prevalence and incidence approaches 91
top-down and bottom-up analyses 91
cost utility analysis (CUA) 91
Counselling, depression in Parkinson’s disease 474
cranial arteritis (temporal arteritis) 124
cranial nerves, examination 120
C-reactive protein (CRP) 123, 470
creatinine 56
Creutzfeldt–Jakob disease (CJD) 373–374
age of onset 373, 374
antemortem diagnosis 374
geneic 373, 375
iatrogenic 375
presenting symptoms 374
prevention/precautions 376
risk factors 374
sporadic 373, 374–375
diagnostic tests 375
EEG 126, 374
subtypes 373
treatments 376–377
variant see variant Creutzfeldt–Jakob disease (CJD)
Criminal Justice Act 2003 851
criminal justice system 696–697
arrest 696
prison 697
trial 696
Crisis Intervention teams 756
cross-cultural epidemiology
dementia 719–724
see also under dementia
depression 717–719
see also under depression (geriatric)
see also cultural differences/influences;
ethnic groups; individual countries/regions
cross-tolerance, drugs 681–682
cryptococcosis 428–429, 430
CNS infection 429
investigations and treatment 429
‘crystallized abilities’ 62
Cuba, dementia prevalence 720
cultural competence 713
cultural differences/influences 713–716
alcohol abuse prevention 668
attitudes to depression 518, 520, 521
caregivers and persons with dementia 327
confidentiality 714
Coping behaviour/abilities 465, 466
dementia 715, 719–724
diagnosis 209, 719
epidemiology 209
see also dementia
depression 714–715, 717–719
effect on functioning 178, 209
effect on normal vs abnormal cognitive ageing 209
families and carers’ roles and needs 714
family caregivers and stress 415–416, 417
mental health assessment 713
neuropsychological assessment 136
psychosis 715
sexual activity and ageing 707
see also cross-cultural epidemiology;
ethnic groups
culture 713
of care, Dementia Care Mapping (DCM) changing 159
of clinical setting 713
of clinician 713
culture-bound syndromes 714
cyclin-dependent kinase 5 (Cdk5) 292
cyclothymia 458
CYP2D6 301
cytochrome P450 enzymes 56
CYP4502D6 56, 538
CYP4502D6 56, 521
cytokines
Down syndrome 282
vascular disease and depression with 470
SUBJECT INDEX

delirium 195–200, 805
active 195
aetiology 196–197
Alzheimer’s disease with 226, 326–327
anaesthetics effect 817–818
cholinergic mechanisms 821–822
costs related to 195, 805
dementia confusion 197–198, 204
dementia with 198, 226, 326–327, 805
diagnosis, missed in general care hospitals 803, 805
diagnosis in offenders 696
differential diagnosis, schizophrenia 599–600
drugs causing 198
DSM-IV diagnostic criteria 195, 196, 204
emergence (after anaesthesia) 817
focused intervention trials, impact 197
history-taking 601
ICD-10 classification 106
incident (after admission to hospital) 805
interval (after anaesthesia) 817–818
investigations 123
liaison psychiatry and 805
malnutrition as risk factor 824
management 197
medical diagnosis with 805
misdiagnosis 195, 196, 803
mixed 195
MMSE in assessment 146
mortality 838
paranoid 600
pathophysiology 196–197
population at risk 196
post-hip fracture 197
postoperative 817–818
predication, IQCODE use 149
predisposing/predisposing factors 818
risk factors 818
presentation and symptoms 195–196
prevalence 195, 805
prevalent (at admission to hospital) 805
prevention 197
quiet 195, 196
rating scales 195
as risk factor for death/dementia 195, 204
risk factors 196, 198, 805, 818, 824
subcategories 195
subsyndromal 196
susceptibility, factors 196, 198
treatment approaches 198–199, 805, 838
behavioural stabilization 198
drug treatment 198–199
treatment of causes 198
‘delirium with Lewy bodies’ 366
Delis-Kaplan battery 391
delusion(s) 114
aetiology 605
Alzheimer’s disease 228, 229, 312, 324
of abandonment 326
as confabulation 326
drug management see antipsychotic drugs
non-pharmacological management 326–327
of theft 114, 229, 312, 326, 600
CBT outcome 606
classification 114
in depression, management 553
incidence/prevalences 597
paranoid 599
Alzheimer’s disease 229, 312
partition 596, 599, 605
persecutory 592, 599, 605
primary 114
schizophrenia 599
types 605
delusional disorder
differential diagnosis 600–601
late-onset 592, 593, 601
late-onset schizophrenia vs 593, 596, 601
organic, schizophrenia vs 600
schizophrenia vs 596
dementia
in 19th century 4
aetiology 723–724
cardiovascular risk factors 723
cross-cultural 719
environmental factors 723, 805, 810
genetic factors 723
nutritional factors 723
aggressive behaviour 229, 695
alcoholic see alcoholic dementia
in Alzheimer’s disease
subtypes (ICD-10 DCR) 106
see also Alzheimer’s disease (AD)
Alzheimer’s disease without 205
anaesthesia effect 817
cholinergic mechanisms 821–822
assessment, NICE guidance 806
behavioural and psychological symptoms (BPSD) 210–211, 312, 719
in Africa 734
assessment 762
management and prevention 762–763
care in
China and Hong Kong 738
ethics see ethics/ethical issues
goals 410, 413
South Asia 731–732
care burden 66, 557, 731
caregivers see caregivers/carers
care homes see care homes
care vs treatment needs 750, 751
causes of death 838
in China 737–738
classification 105–108, 201–206, 342
10/66 group criteria 204–205
‘Alzheimerization’ 204
current systems 201
DSM-IV 107
DSM-IV-TR 201, 202, 208
future challenges 204–205
future groupings 107
historical background 203–204
ICD-10 105–106, 201–202, 203, 208
NINCDS-ADRDA 201, 202–203
co-morbidity 208, 763–764
consent for sexual relations 75
costs related to 207–208, 722
cross-cultural variation 719–724
aetiology of dementia 723–724
Africa 734
diagnosis validity 719–720
impact and costs 722–723
prevalence 719, 720–722
prevention 723–724
research, history 719–720
day hospitals role 753, 754
discharges and evaluation 754
definition 202, 208, 342, 719
ICD-10 106
delirium confusion 197–198, 204
delirium superimposed 805
delirium as 195, 204
learning disability with see learning disability
liason psychiatry and 805–806
life expectancy 838
long-term care 9, 749–750, 751, 812
in US 791, 793, 812
losses experienced in/psychological impact 80
low awareness/hidden problem, South Asia 730
malnutrition association 825, 826
feeding issues 826
management, cognitive stimulation 813
neuropathological factors associated 218
neuropsychological assessment see neuropsychological assessment
NHS continuing care for 759, 760
nosology see dementia, classification ‘not otherwise specified’ (ICD-10) 107
‘not otherwise specified’ (ICD-10) 107
nutrition and feeding in 826–827
offences in/offenders 695, 696, 697
sexual 694, 697
pain 840
palliative care 838
indications 839–840
international perspective 838–839
principles 839
person-centred home support team 812
physical illnesses 763–764
prevalence/incidence 208, 216, 217, 271
affluent vs low-/middle-income countries 208
in Africa 734, 735
age relationship 272, 720
apoE genotype 216, 217
in care homes (UK) 524
in China (incidence) 737–738
in China (prevalence) 737
neurocognitive functioning patterns 233–234
staging procedure (FAST); Global Deterioration Scale (GDS)
stigma 719
in stroke see stroke
subtypes 208
suicidal behaviour and 560, 806
as superspecialty of geriatric psychiatry 862
supportive care 810
treatment 205
in China 738
effects on brain function 32
ethical aspects 412–413
group therapy, private hospitals 798
of offenders 698
vascular see vascular dementia (VaD)
vitamin B12 deficiency-induced 123
voting despite, ethics 412
weight loss 826
well-being, Dementia Care Mapping
focusing on 157, 158
SUBJECT INDEX 877
dementia continued
without memory impairment 208
see also Alzheimer’s disease (AD)
Dementia Advocacy and Support Network (DASN) 423, 424
Dementia Care Mapping (DCM) 78–79, 157–161, 325, 761
advantages 159, 160
aspects evaluated 158
behavioural category code (BCC) 158, 160
bibliographic database 159
consistency of findings 158
culture of care changes using 159
dependency measure with 159
development 157–158
International Implementation Group 157
mood/engagement value (ME value) 158
observation period length 158
personal detractions and enhancers 158
person-centred care 157, 159
populations indicating use 159
reliability 158–159
research use of 159–160
tool, evaluation, and mapping 158
training 157
translation and international use 157
uses 157, 159–160
translation and international use 157
training 157
well-being score (WIB score) 158, 159
validity 158
well-being score (WIB score) 158, 159
dementia of Alzheimer type (DAT) see Alzheimer’s disease
‘dementia only’ services 750
dementia paralytica 428
dementia praecox 591
Dementia Quality of Life measure 187
Dementia Scale (DS) of Blessed 170
Dementia Screening Questionnaire for Individuals with Intellectual Disabilities (DSQIID) 690
dementia with Lewy bodies (DLB) 360
AD with brain functional changes 30
classification 361, 362–363
DSM-IV-TR 201
clinical diagnosis 366
clinical features 364–366
consciousness alterations 204
consensus criteria 362, 363
validation 363
differential diagnosis 366
AD 365
PDD 363
EEG 126
epidemiology 364
genetic testing 127
investigations and biomarkers 366–367
management 367–369
probable and possible, diagnosis 362, 363
risk factors 364
temporal order of Lewy body progression 360
see also Lewy body dementias
demographics and ageing 83–89, 207, 717
Africa 734
changing health status in older people 85–86
China 737
disability trends 87–88
elderly population 55, 90, 100
by country 86
fertility rates 83–84, 207
future prospects/directions 88
healthy life expectancy see healthy life expectancy
India and China 85
life expectancy trends 84–85
oldest old group 88
population size trends 83, 717
post/during World War II 7
South Asia 730
UK 84, 524
USA 84, 100, 421, 772–773, 857

see also Alzheimer’s disease
without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)

without memory impairment 208
see also Alzheimer’s disease (AD)
incidence, preventive interventions effect 520
language used to describe 520
late-onset 97, 460, 496
as distinct type 496
early-onset vs 496, 566–567
genetics 461
in Lewy body dementias 365
liaison psychiatry and 510, 806
in long-term care (in US) 791, 793
low cholesterol and 469, 826
magnetic resonance spectroscopy 448–450, 492
major 495–496
classification 457–458
default mode network (DMN) role 30
diagnostic criteria/features 496
differential diagnosis 565–566
incidence prevention 846–847
long-term care (in US) 791, 793
outcome 504
prevalence 495, 508, 565, 844
prevention 844
PTSD vs 642
risk of developing 847
sociodemographic correlates (cross-cultural) 718–719
symptoms 457, 565–566
treatment, effects on brain function 32
malnutrition association 825
management 525–526
acute see above
collaborative care approach 526
exercise 525
policy implications 526–527
stepped care approach 525
see also depression (geriatric), treatment
‘masked’ 638
melancholic 566, 567
Mental State Examination 114
minor/mild 495, 566
classification 459
outcome 504
in Parkinson’s disease 473, 474, 477
prevalence 508, 617
mixed anxiety and depressive disorder 612
morbidty 505, 509
mortality 505, 509, 617
cardiovascular outcomes and 619
in hospital 509
neuromaging see neuroimaging
neurotic, ECT for 530
older adults’ attitudes to seeking help 520–521
older adults’ concept of 518, 520, 521
outcome 502–507, 538
defining and measuring 503
episodic model 503
excess/inadequate use of health services 505
excess morbidity 505
excess mortality 505
generic 505
pleiomorphic 503, 504
poor, physical illness association 511–512
variability 502, 504–505
well-being and functioning 505
in Parkinson’s disease see Parkinson’s disease (PD)
persistent in grief 498
post-stroke 515
personality disorders with 498, 651–652
physical illness with 498, 499–500, 508–514, 567–568
adjustment disorder 510
aetiology 618–619
assessment/screening scales 511
cardiocvascular 505, 509
CNS disease 552, 567, 569
depression due to 509
depression impact on 505
diagnosis 500, 508, 552
epidemiology 508
hospitalization indications 552, 553
impact on medical treatments 565
inclusive vs aetiological approaches 567
liaison 510–511
mental state examination 568
morbidity/mortality 509
Parkinson’s disease see Parkinson’s disease (PD)
prevalence 565, 618–619
prognosis 511–512
rehabilitation 810
service implications 512
treatment 511
post-stroke see stroke, depression after
prevalence 97, 495, 508, 518, 844
Africa 485, 486
after stroke 515
Americas 480, 482, 483
Asia 482–485
Australia 485
in care homes (UK) 524
China 739
Europe 479–480, 481
low-/middle-income countries 718
major depression 495, 508, 565, 844
minor/mild depression 508, 617
sociodemographic correlates (cross-cultural) 718–719
South Asia 731
prevention 562, 846
CBT and Coping with Depression 846
identifying target groups for 847
indicated 846
life review and reminiscence 846
in residential care 845
selected 845
stepped-care models 846
primary care professionals’ perceptions 521
prognosis 502
age/age-related factors affecting 504
in medical setting 511–512
pleiomorphic not episodic 503
systematic reviews 503–504
variability 502, 504–505
prognostic factors 504
culturally sensitive 526
discontinuities in system for 518
drug therapy after ECT 530
ECT see electroconvulsive therapy
ECT in general hospitals 806
inadequacy 511
in medical psychiatric inpatient unit 788
personality disorder impact 652
pharmacological 537–542
post-stroke 516
pre-treatment considerations 537
repetitive transcranial magnetic stimulation (rTMS) 534
in residential homes 526
response, MRI volumetric studies 489–490
see also antidepressants; depression (geriatric), management
treatment-resistant antidepressant management 539–540
ECT for 550
unipolar 496
unipolar to bipolar switch 577
‘vascular’ see vascular depression
vascular disease and 468–472, 487
depression as risk factor for 469, 497
depression complicating 468, 496–497
relationship mechanisms 469–470
suicide prevention/risk 560, 561
treatment 470
vulnerability 496
white matter hyperintensities (WMHs) 490, 496
without sadness 114, 496
depression–executive dysfunction syndrome 458, 468, 474
‘depression of Alzheimer’s disease’ (dAD) 228
see also under depression (geriatric), management
depressive episode
classification 457–458
major see depression, major
minor 457
depressive pseudodementia 386, 474
depressive syndromes 565–572
depression of liberty 10, 761, 853
Deprivation of Liberty Safeguards (DOLS) 761, 851, 853
desflurane 822
desipramine 537
in anxiety/anxiety disorders 628
developmental disability, in offenders 696
dexamethasone suppression test (DST) 569
dexamethasemodimide, delirium management 199
DHA-derived neuroprotectin D1 (NPD1) 404
dhat 714
diabetes mellitus
beta-amyloid clearance reduction 272–273
depression as risk factor 469
depression complicating 468
insulin-dependent, ECT contraindication 531
myo-inositol changes 448–449
Diagnostic and Statistical Manual of Mental Disorders IV see DSM-IV
dialectical behaviour therapy (DBT) 546
personality disorders 658
studies/trials using 546
diazepam
half-life 680
metabolism 56
pharmacodynamics 58
diet
AD prevention 275
memory improvement 403–404
see also nutrition; nutritional deficiencies
dietary restriction, longevity and 53
differential reinforcement 325
diffuse plaques 287
diffusion tensor imaging (DTI)
alcoholic dementia 379
effects of ageing 18
limitations 21
normal ageing 17, 18
quantification of data 18
regional quantification of data 18
white-matter lesions in depression 490–491
diltiazem, pharmacodynamics 58
diphenhydramine, pharmacodynamics 58
directly managed units (DMUs) 746
Direct Observation of non-Clinical Skills (DoNCS) 862
disability 66
assessment of extent 811
care home residents 78
cognitive impairment contributing to 67
definition 66
depression aetiology 719
levels, age-specific trends 87–88
physical/mental disorder contribution 722–723
prevalence 207
affluent vs non-affluent countries 207
increase in and concerns over 183
in terms of activities of daily living 66–67
progressive nature 763
risk with alcohol use 676
weighting, of dementia 722
disability adjusted life years (DALYs) 176
Disability Assessment for Dementia (DAD) 305
disability-free life expectancy 67
‘disability paradox’ 184, 186
disclosure avoidance (by patients), personality disorders 655–656
discrimination
age-based (Equality Bill 2009) 525
elderly people with learning disability 692
against lesbian, gay and bisexual (LGB) people 76
disengagement theory 731
economics of ageing 90–96
see also cost(s); health economics

economic stress, carers of dementia 731

ectodomain shedding 289

education

coping behaviour link 465

as dementia risk factor 209

depression prevalence correlation 719

effect on normal vs abnormal cognitive ageing 209

geriatric psychiatry see training

health link 464

healthy/affordable eating 826

liaison psychiatry 804–805

long-term care staff 791

MMSE and 145

nutrition 826, 827

by private practitioners 780

professional

liaison psychiatry 804–805

medical psychiatric inpatient unit 789

suicide prevention strategy 561, 562

see also training

EEG see electroencephalography (EEG)

eicosapentaenoic acid (EPA) 275, 404

eigenvalues 18

ejaculation 706

deposits 708

premature 708

problems 707

electrical stimulation 163

elder abuse 835–837

abuser characteristics 836

categories 835

definition 835

domestic 835

institutional 835, 836

management 836

natural history 836

physical 835, 836

prevalence and incidence 835

psychological 835, 836

recognition 836

risk factors 835, 836

signs and symptoms 837

victim characteristics 835–836

Elder Life Program, The 805

‘elderly adolescentism’ 559

elderly people see older people; specific topics

electrocardiography (ECG) 125–126, 345

electroconvulsive therapy (ECT) 529–536

administration 532

adverse effects 530, 531, 533

bilateral vs unilateral electrode placement 532

bipolar disorder 582

brief pulse 532, 533

consent 529, 533

contraindications 531–532

depression 511, 529–530, 532, 563

continuation pharmacotherapy after maintenance and c ontinuation 532–533

mania 531

modified, in China 739

NICE guidance 530, 531, 533

obsessive–compulsive disorder 634

outpatient 532

psychiatric history-taking 110

schizophrenia 531

seizures during 532

Electroencephalography (EEG) 126

Creutzfeldt–Jakob disease (CJD) 126, 374

Lewy body dementias 366

neurofeedback for cognitive enhancement 406

quantitative (qEEG) 126

rhythms

normal aging (resting EEG) 38

quantitative 39

surface Laplacian transformation (coherence analysis) 38

sleep, in depression 569

electrolytes, alcohol abuse effect on 666

electromyogram (EMG) 702

Ely Hospital Report (1969) 9

embryonic stem cells (ESCs) 330, 334, 335

Emergency Medical Service (EMS) 745–746

emotional blunting

frontotemporal dementia 348

PTSD 641

emotional distress

distinction with mental illness 97

presentations in different cultural groups 714

see also distress; stress

emotional liability 114

empowering elderly people 848

enalapril, pharmacodynamics 58

encephalitis, herpes simplex see herpes simplex encephalitis

encephalopathy, bismuth 380

dermatology, effects on CNS 45

end-of-life care

indications 839–840

legal frameworks, NHS continuing care 761

NHS continuing care 764–765

people with learning disability 692

see also palliative care

endoscopy 124

endothelial dysfunction, vascular disease and depression 470

enhanced outpatient treatment programme 801

Enriched Opportunities Programme 81

enteral nutritional support, decision on, ethics 413

entorhinal cortex, neurofibrillary tangles 295
<table>
<thead>
<tr>
<th>SUBJECT INDEX</th>
<th>883</th>
</tr>
</thead>
<tbody>
<tr>
<td>Environment</td>
<td>effect on functional abilities 178</td>
</tr>
<tr>
<td></td>
<td>management for behavioural stabilization in delirium 198</td>
</tr>
<tr>
<td></td>
<td>environmental antecedents/sequences 324</td>
</tr>
<tr>
<td></td>
<td>environmental enrichment, neurogenesis improvement 332, 333</td>
</tr>
<tr>
<td></td>
<td>environmental factors</td>
</tr>
<tr>
<td></td>
<td>Alzheimer's disease 301, 723</td>
</tr>
<tr>
<td></td>
<td>coping abilities and 464–467</td>
</tr>
<tr>
<td></td>
<td>diverse/restricted social networks 466</td>
</tr>
<tr>
<td></td>
<td>depression aetiology 618</td>
</tr>
<tr>
<td></td>
<td>depression prediction (late-life) 461</td>
</tr>
<tr>
<td></td>
<td>sporadic AD induction/prevention 293</td>
</tr>
<tr>
<td></td>
<td>environmental vulnerability model 324, 325</td>
</tr>
<tr>
<td></td>
<td>eosinophilic neuronal inclusion bodies see Lewy bodies</td>
</tr>
<tr>
<td></td>
<td>Epidemiologic Catchment Area Study (ECA) 576, 597, 617</td>
</tr>
<tr>
<td></td>
<td>alcohol abuse 671</td>
</tr>
<tr>
<td></td>
<td>illicit drug misuse 681</td>
</tr>
<tr>
<td></td>
<td>OCD prevalence 633</td>
</tr>
<tr>
<td></td>
<td>epidermal growth factor receptor (EGFR) 332</td>
</tr>
<tr>
<td></td>
<td>epidermal growth factor (EGF) 332</td>
</tr>
<tr>
<td></td>
<td>Epidemiology 207</td>
</tr>
<tr>
<td></td>
<td>Alzheimer's disease see Alzheimer's disease (AD)</td>
</tr>
<tr>
<td></td>
<td>anxiety disorders 619–620</td>
</tr>
<tr>
<td></td>
<td>cerebrovascular disease 208, 343–344</td>
</tr>
<tr>
<td></td>
<td>cross-cultural see cross-cultural epidemiology</td>
</tr>
<tr>
<td></td>
<td>dementia see dementia</td>
</tr>
<tr>
<td></td>
<td>depression see depression disabilities 87–88</td>
</tr>
<tr>
<td></td>
<td>Down syndrome 281</td>
</tr>
<tr>
<td></td>
<td>Global Mental Health Assessment Tool (GMHAT) 174, 175</td>
</tr>
<tr>
<td></td>
<td>GMS-HAS-AGECAT package 174–175</td>
</tr>
<tr>
<td></td>
<td>insomnia 700, 701</td>
</tr>
<tr>
<td></td>
<td>Lewy body dementias 364</td>
</tr>
<tr>
<td></td>
<td>‘life course’ 211</td>
</tr>
<tr>
<td></td>
<td>longitudinal studies 86</td>
</tr>
<tr>
<td></td>
<td>mania 573, 576, 600</td>
</tr>
<tr>
<td></td>
<td>mental health changes 88</td>
</tr>
<tr>
<td></td>
<td>OCD 633</td>
</tr>
<tr>
<td></td>
<td>Parkinson’s disease 473–474</td>
</tr>
<tr>
<td></td>
<td>personality disorders 651–652, 655</td>
</tr>
<tr>
<td></td>
<td>schizophrenia 596–597, 604</td>
</tr>
<tr>
<td></td>
<td>vascular dementia 343–344</td>
</tr>
<tr>
<td></td>
<td>epidermal growth factor (EGF) 332</td>
</tr>
<tr>
<td></td>
<td>epidermal growth factor receptor (EGFR) 291</td>
</tr>
<tr>
<td></td>
<td>epilepsy</td>
</tr>
<tr>
<td></td>
<td>ECT contraindication and 532</td>
</tr>
<tr>
<td></td>
<td>in learning disability 691</td>
</tr>
<tr>
<td></td>
<td>episodic memory 131, 390, 397</td>
</tr>
<tr>
<td></td>
<td>anterograde 131</td>
</tr>
<tr>
<td></td>
<td>assessment tests 390</td>
</tr>
<tr>
<td></td>
<td>hippocampus volume reduction 489</td>
</tr>
<tr>
<td></td>
<td>impairment in AD 439</td>
</tr>
<tr>
<td></td>
<td>prefrontal cortex 37</td>
</tr>
<tr>
<td></td>
<td>preserved in LBD 365</td>
</tr>
<tr>
<td></td>
<td>retrograde 131</td>
</tr>
<tr>
<td></td>
<td>testing 131</td>
</tr>
<tr>
<td></td>
<td>EQ-5D EuroQol Group measure 186, 187</td>
</tr>
<tr>
<td></td>
<td>Equality Act 2006 10</td>
</tr>
<tr>
<td></td>
<td>Equality Bill 2009 525</td>
</tr>
<tr>
<td></td>
<td>erectile dysfunction 707, 708</td>
</tr>
<tr>
<td></td>
<td>treatment 708</td>
</tr>
<tr>
<td></td>
<td>erection, penis 706</td>
</tr>
<tr>
<td></td>
<td>Erikson, Erik 650</td>
</tr>
<tr>
<td></td>
<td>errorless learning 398</td>
</tr>
<tr>
<td></td>
<td>erythrocyte sedimentation rate (ESR) 123</td>
</tr>
<tr>
<td></td>
<td>established populations for epidemiologic studies of the elderly (EPESE) 672</td>
</tr>
<tr>
<td></td>
<td>ethics, clinical, principles 766–767</td>
</tr>
<tr>
<td></td>
<td>ethics/ethical issues 766–767, 766–769, 767–768</td>
</tr>
<tr>
<td></td>
<td>of care 767</td>
</tr>
<tr>
<td></td>
<td>cost-effectiveness analysis (CEA) 95</td>
</tr>
<tr>
<td></td>
<td>dementia care 410–414</td>
</tr>
<tr>
<td></td>
<td>diagnosis disclosure 411</td>
</tr>
<tr>
<td></td>
<td>presymptomatic stage 410</td>
</tr>
<tr>
<td></td>
<td>quality of life goal 410, 413</td>
</tr>
<tr>
<td></td>
<td>safety (personal) issues 413</td>
</tr>
<tr>
<td></td>
<td>therapy decisions 412–413</td>
</tr>
<tr>
<td></td>
<td>dementia research participation 412</td>
</tr>
<tr>
<td></td>
<td>driving in dementia 412</td>
</tr>
<tr>
<td></td>
<td>genetic tests 127</td>
</tr>
<tr>
<td></td>
<td>incapacity management 411</td>
</tr>
<tr>
<td></td>
<td>law and 766–769, 850</td>
</tr>
<tr>
<td></td>
<td>person-centred 768–769</td>
</tr>
<tr>
<td></td>
<td>personhood and 768–769</td>
</tr>
<tr>
<td></td>
<td>psychotic disorder treatment 604</td>
</tr>
<tr>
<td></td>
<td>research and 769</td>
</tr>
<tr>
<td></td>
<td>spiritual support 743</td>
</tr>
<tr>
<td></td>
<td>virtue 767</td>
</tr>
<tr>
<td></td>
<td>voting in dementia 412</td>
</tr>
<tr>
<td></td>
<td>ethnic groups 713</td>
</tr>
<tr>
<td></td>
<td>apoE and Alzheimer’s disease 246</td>
</tr>
<tr>
<td></td>
<td>communication issues 714</td>
</tr>
<tr>
<td></td>
<td>coping behaviour/abilities 465, 466</td>
</tr>
<tr>
<td></td>
<td>demographics in UK 524</td>
</tr>
<tr>
<td></td>
<td>depression barriers on pathway to care 518–519, 519–520, 522</td>
</tr>
<tr>
<td></td>
<td>diagnosis problems 524–525</td>
</tr>
<tr>
<td></td>
<td>facilitators to care 519–520</td>
</tr>
<tr>
<td></td>
<td>GP consultation 525, 526</td>
</tr>
<tr>
<td></td>
<td>implications for policy/practice 521–522</td>
</tr>
<tr>
<td></td>
<td>lack of ‘psychological-mindedness’ 521</td>
</tr>
<tr>
<td></td>
<td>language used to describe 520</td>
</tr>
<tr>
<td></td>
<td>older adults’ attitudes to seeking help 520–521</td>
</tr>
<tr>
<td></td>
<td>older adults’ concepts 518, 520</td>
</tr>
<tr>
<td></td>
<td>prevalence 518, 524</td>
</tr>
<tr>
<td></td>
<td>emotional stress not medicalized 521</td>
</tr>
<tr>
<td></td>
<td>family caregivers and stress 415–416</td>
</tr>
<tr>
<td></td>
<td>Geriatric Depression Scale use 154</td>
</tr>
<tr>
<td></td>
<td>geriatric psychiatrists in UK 860</td>
</tr>
<tr>
<td></td>
<td>mental health assessment 713</td>
</tr>
<tr>
<td></td>
<td>USA, bereavement issues 557–558</td>
</tr>
<tr>
<td></td>
<td>see also black Caribbean people (UK); cultural differences/influences; South Asians (in UK)</td>
</tr>
<tr>
<td></td>
<td>EURODEM, dementia prevalence/incidence 720</td>
</tr>
<tr>
<td></td>
<td>EURODEP study 479–480, 617</td>
</tr>
<tr>
<td></td>
<td>EURODERM 222</td>
</tr>
<tr>
<td></td>
<td>European Test Battery 818</td>
</tr>
<tr>
<td></td>
<td>EuroQoL (EQ-5D) measure 186, 187</td>
</tr>
<tr>
<td></td>
<td>euthanasia 838–839</td>
</tr>
<tr>
<td></td>
<td>event-related desynchronization (ERD) 39</td>
</tr>
<tr>
<td></td>
<td>event-related synchronization (ERS) 39</td>
</tr>
<tr>
<td></td>
<td>Everybody’s Business – Integrated Mental Health Services for Older Adults (CSIP, 2005) 526</td>
</tr>
<tr>
<td></td>
<td>Everyday Abilities Scale for India (EASI) 730</td>
</tr>
<tr>
<td></td>
<td>evidence-based treatment 417</td>
</tr>
<tr>
<td></td>
<td>for family caregivers 417</td>
</tr>
<tr>
<td></td>
<td>US mental health care 774</td>
</tr>
<tr>
<td></td>
<td>evolution, role of ageing 51</td>
</tr>
<tr>
<td></td>
<td>examination mental state see Mental State Examination (MSE)</td>
</tr>
<tr>
<td></td>
<td>physical see physical examination excessive daytime sleepiness (EDS) 703</td>
</tr>
<tr>
<td></td>
<td>executive dysfunction 133</td>
</tr>
<tr>
<td></td>
<td>Alzheimer’s disease 227, 232, 393, 690</td>
</tr>
<tr>
<td></td>
<td>bipolar disorder 579</td>
</tr>
<tr>
<td></td>
<td>dementia classification 204</td>
</tr>
<tr>
<td></td>
<td>detection, tests 391–392</td>
</tr>
<tr>
<td></td>
<td>Down syndrome 283, 690</td>
</tr>
<tr>
<td></td>
<td>effect on functional abilities 178</td>
</tr>
<tr>
<td></td>
<td>Lewy body dementias 365</td>
</tr>
<tr>
<td></td>
<td>executive dysfunction syndrome, in Alzheimer's disease 230</td>
</tr>
<tr>
<td></td>
<td>executive function 232</td>
</tr>
<tr>
<td></td>
<td>abilities/processes included 391</td>
</tr>
<tr>
<td></td>
<td>age-related decline 227</td>
</tr>
<tr>
<td></td>
<td>assessment 132–133, 205, 391–392</td>
</tr>
<tr>
<td></td>
<td>frontal lobe role 234</td>
</tr>
<tr>
<td></td>
<td>impairment see executive dysfunction exercise</td>
</tr>
<tr>
<td></td>
<td>AD management 326</td>
</tr>
<tr>
<td></td>
<td>AD prevention 275</td>
</tr>
<tr>
<td></td>
<td>benefits 406, 407</td>
</tr>
<tr>
<td></td>
<td>dementia prevention 210, 275</td>
</tr>
<tr>
<td></td>
<td>depression management 525</td>
</tr>
<tr>
<td></td>
<td>mechanism of benefits 407</td>
</tr>
<tr>
<td></td>
<td>memory improvement 406–407</td>
</tr>
<tr>
<td></td>
<td>mindful (yoga), memory improvement 406</td>
</tr>
<tr>
<td></td>
<td>neurogenesis improvement 332, 333</td>
</tr>
<tr>
<td></td>
<td>expanded rehearsal (spaced retrieval) 326, 398</td>
</tr>
<tr>
<td></td>
<td>expenditure on health NHS 746, 747–748</td>
</tr>
<tr>
<td></td>
<td>US 771, 772</td>
</tr>
<tr>
<td></td>
<td>increasing with time 772–773</td>
</tr>
<tr>
<td></td>
<td>see also cost(s)</td>
</tr>
<tr>
<td></td>
<td>Explanatory Models Approach 713</td>
</tr>
<tr>
<td></td>
<td>exposure and response prevention (ERP) therapy 633</td>
</tr>
<tr>
<td></td>
<td>exposure rate (ER) 847</td>
</tr>
<tr>
<td></td>
<td>external coherence 767, 768</td>
</tr>
<tr>
<td></td>
<td>extra care housing 814</td>
</tr>
<tr>
<td></td>
<td>extraocular muscle function, assessment 210, 275</td>
</tr>
<tr>
<td></td>
<td>executive dysfunction 326</td>
</tr>
<tr>
<td></td>
<td>execrational muscle function, assessment 120</td>
</tr>
<tr>
<td></td>
<td>extrapyramidal signs 133</td>
</tr>
<tr>
<td></td>
<td>eyes examination 120</td>
</tr>
</tbody>
</table>
eyes 118
  inspection
  movements, assessment 133

face–name associations 398
  functional MRI (fMRI) 439

facial recognition impairment, semantic 398
  face recognition impairment, semantic
  face–name associations 398

family caregivers 91, 415–420
  extended, depression management 526

families
  care role, US private practice and 781
  communication with, long-term care in US 791, 792
  contact with, in schizophrenia 604
  dementia care by, in China 738
  different cultures 714
  disability affecting, rehabilitation and 811
  dysfunctional relationships, alcohol abuse and 666
  end-of-life issues, NHS continuing care 764
  extended, depression management 526
  informal carers 91
  multigenerational transactions 464
  role in depression management 526
  structure changes in China 738
  depression in South Asia 731

  dementia care in South Asia 732
  in depression, ethnic groups 520
  lacking, depression associated 520

Family Caregiver Alliance 422, 424
  family caregivers 91, 415–420

assessment (health/stress levels) 416–417
  diverse ethnic groups 417
  domains to assess 416–417
  best practices for supporting 417–418
  evidence-based treatments 417–418
  individualization 417, 418
  multi-component treatments 418
  programmes 418, 419
  care recipient’s behavioural impairments 830, 832

  definition 829
  dementia vs non-dementia 830
  ethnic groups and cultural diversity 415–416, 417

health impact of caregiving 415, 830–831
  anxiety 831
  depression 830–831
  mental health outcomes 415, 830–831
  physical health outcomes 831
  knowledge about dementia 416, 417

  positive and negative outcomes 830
  public policy and cost implications 829
  relocating recipient to nursing homes 831–832
  resources for 417
  social support for 417
  stress 415–416, 829, 830

  assessment 416
  factors affecting 415, 830
  models 829–830
  stressors 830
  support groups 418–419
  support services 418–419, 831–832

see also caregivers/carers

Family Caregivers Alliance 416
  family history
  Alzheimer’s disease 238, 246
  bipolar disorder 577, 579
  as dementia risk factor 209
  depression 486–487, 568
  FTD 353
  psychiatric history-taking 110

Family Involvement in Care (FIC) 832

family psychoeducational programme, psychiatric disorders 606
  fast axonal transport (FAT), APP transport 291

  fat, body, increase with age 56

fat, body, increase with age 56
  fast axonal transport (FAT), APP transport 291

fatigue syndrome see neurasthenia

[18F]FDDNP-PET 259–260, 264

FDG-PET scans 28, 258–259, 437
  Alzheimer’s disease 259
  frontotemporal dementia 30, 31, 350
  frontotemporal lobar degenerations 30, 31, 350

fear
  of ageing 495
  in elderly 614
  feeding, ability to 764
  fentanyl 199
  ferritin, grey matter, in ageing 21–22
  fertility, trends 83–84, 207
  fibrillogenesis, increased 287
  fibroblast(s), in Alzheimer’s disease 300
  fibroblast growth factor 2 (FGF-2) 334
  ‘fight-or-flight’ response 47

  financial issues, psychiatric history-taking 111
  five-factor model (FFM), personality traits 656
  FLAIR images 434
  flashback episodes 640
  PTSD 641
  flashbulb memories 62
  ‘fluid abilities’ 62
  fluorine-18 28
  18F-fluoro-2-deoxy-glucose (FDG)-PET
  PET see FDG-PET scans

  fluoxetine
  in anxiety 628
  in depression 538
  in dysthymia 498

  with rivastigmine 308
  flupentixol, absorption 55

fluoxetine
  in Alzheimer’s disease 319
  in anxiety 628
  in treatment-resistant depression 539
  focal psychotherapy, adjustment disorder 642

folate deficiency 123
  dementia aetiology 723
  folate supplements 404, 407
  Alzheimer’s disease 308
  follicle-stimulating hormone (FSH) 46

food intake
  alcohol abuse and 666
  reduced, in dementia 764

see also diet; nutrition

forensic historians, psychiatric history-taking 112

forensic psychiatrists 696, 697, 698

forgetting, age-related 499

Forkhead transcription factors 53

forward-digit span 131
‘Foundation’ Trusts 747

FOX1A gene 53

FP-CIT 366

fractional anisotropy 18, 20, 21
  white-matter lesions in depression 491

frailty 66, 196

frailty index 66

France
  depression prevalence 480
  palliative care 838
  free radicals 282
  Freud, Sigmund 611, 633, 636, 650

frontal ageing hypothesis 61

frontal brain, volume reduction in normal ageing 17

frontal lobe
  executive functioning 234
  NAA decrease in normal ageing 447
  frontal lobe dementia, forensic history and offence 112
  frontal lobe lesions 37

frontolimbic region, fMRI activation, depression 491

frontotemporal dementia (FTD) 348
  behavioural variant (bvFTD)

Addenbrooke’s Cognitive Assessment 131
  age of onset 348
  behavioural changes 130, 235
  classification, DSM-IV-TR 201
  clinical presentation 348–349
  evaluation, diagnosis and imaging 30, 31, 350–351
  incidence 348

  left-sided atrophy 350
  memory impairment not main symptom 204, 348

mutations 127, 353

pathology and neurogenetics 351–353

right temporal variant 132

brain functional changes 30, 350

cognitive impairment, personality disorders vs 657

learning disability with 689

magnetic resonance spectroscopy 451
offenders 696
as a proteinopathy (tau) 377
treatment 353
effect on brain function 32
frontotemporal dementia (FTD) syndromes 348–359
behavioural variant (bvFTD) see
frontotemporal dementia (FTD)
clinical evaluation and diagnosis 350–351
clinical features 348–350
course and management 353
FTDP-IF 353
FTDP-MND 353
FTDP-ni 353
FTDP-U 353
FTDP-UPS 353
histopathology of variants 352
pathology and neurogenetics 351–353
PNFA see progressive non-fluent aphasia (PNFA)
semantic dementia see semantic dementia (SD)
variants, relationship between 351–352
frontotemporal dementia with Parkinsonism on chromosome 17 (FTDP-17) 253, 353
P301L mutation 253
frontotemporal lobar degenerations 351
asymmetric atrophy, progressive
non-fluent aphasia (PNFA) 349
brain functional changes 30
F-spondin 293
functional abilities 176–182
age of onset of condition affecting 178
in Alzheimer’s disease 227
improvement (non-pharmacological interventions) 326
assessment 176–177
by family and clinicians 177
measures/rating scales 179–181
normative basis 176
preference-weighted approaches 176–177
‘core’ set 176
cultural factors affecting 178
decision-making capacity 177
environment affecting 178
impaired see functional decline/changes
influences affecting 177–178
‘recovery’ 177
social functioning 177
see also activities of daily living (ADL);
functional capacity; functional health status; life skills
functional ageing 65–69
concept development 66
see also functional health status
Functional Assessment Staging procedure (FAST) 162, 166
advantages 166
as Medicare ‘gold standard’ 166
MMSE relationship 166
neuronal number decline 166, 167
time course of changes (normal to AD) 163
functional capacity 176
impaired see functional decline/changes
model 178–179
neuropsychological performance 179
see also functional abilities
functional compensation theory 438–439, 440, 441
functional decline/changes 30–32
adaptation and compensation 29
Alzheimer’s disease 29–30
dementia treatment effects 32
frontotemporal dementia 30
frontotemporal lobar degenerations 30
Lewy-body associated disorders 30
mild cognitive impairment 29–30
neurodegenerative disorders 29–30
non-fluent progressive aphasia (NFPA) 30
normal ageing 29
semantic dementia 30
functional disability, model 178–179
functional disorders
community mental health team
management 756
day hospitals 754
treated in private psychiatric hospitals
(US) 796
functional health status 65–67
cognitive function 66
factors affecting 66–67
frailty 66
long-term trends and policy implications 67
performance measures 66
self-reported 66
see also disability; functional abilities
functional imaging 28–35, 36
benefits 28
clinical applications 32
depression (geriatric) 491–492
frontotemporal dementia 350
MRI see functional MRI (fMRI)
techniques 28–29
functional limitation, definition 66
activation, definition 438
activation in MTL
changes in AD 439–440
changes in MCI 440–441
normal ageing 439
see also medial temporal lobe (MTL)
in AD 439–440
advantages 437
applications 435, 437
blocked and event-related designs 435
deaactivation 438, 439
in depression 491
hyperactivation in MTL 441, 442
hypoactivation in MTL 441, 442
methodological challenges in older people 435
neural networks supporting memory
function 439
neural networks supporting memory
function 439
neural networks supporting memory
function 439
normal ageing 438–439
pharmacological, drug efficacy in AD/MCI 442
physiological basis 437–438
resting state (rs-fMRI) 32, 439
task-related 437
functional neuroimaging see functional imaging
functional specialization studies 29
functional units, age-related loss 55
funding
behavioural management, in AD 327
geriatric psychiatrists’ training 858
mental health workforce study in US 858
NHS 747–748
rehabilitation 812, 813
research 8
short-termism 813
US geriatric mental health care see
Medicaid (US); Medicare (US)
see also cost(s)
furomide, pharmacodynamics 58
GABA 36
in AD 296
delinium pathophysiology 197
magnetic resonance spectroscopy 446
gag reflex, testing 120
gait
assessment 121, 130
cerebrovascular disease 130
instability, Parkinson’s disease dementia 365
Lewy body dementias 365, 366
normal pressure hydrocephalus 130
Parkinson’s disease 130
galantamine 305
Alzheimer’s disease 296–297
cognitive benefits 305
donepezil comparison 306
dosing 305, 314
effect on brain function 32
Lewy body dementia 367–368
neuropsychiatric effects 308
side effects 305, 314, 368
gamma glutamyl transpeptidase (γGT) 123
gastric acid, secretion 55
gastrointestinal system, examination 119
gaze, supranuclear 133
gender
affective disorder risk 460
alcohol abuse, age of onset 674
alcohol abuse prevalence 672
Alzheimer’s disease risk 271
apoE and Alzheimer’s disease 245, 246, 271
benzodiazepine misuse 681
brain atrophy in alcohol abuse 379
cooping abilities and resource deficits 466
dementia incidence, Lundby study 222, 223, 224
as dementia risk factor 209
depression aetiology 618, 719
depression prevalence 618
sociodemographic correlates (cross-cultural) 718
Down syndrome 282
social networks 719
### SUBJECT INDEX

<table>
<thead>
<tr>
<th>Term</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>gender continued</td>
<td>618</td>
</tr>
<tr>
<td>social support (late-life)</td>
<td>719</td>
</tr>
<tr>
<td>vascular dementia and AD prevalence</td>
<td>719</td>
</tr>
<tr>
<td>gene(s)</td>
<td>461</td>
</tr>
<tr>
<td>candidate, depression (late-life)</td>
<td>461</td>
</tr>
<tr>
<td>therapy</td>
<td>461</td>
</tr>
<tr>
<td>see also genetics</td>
<td></td>
</tr>
<tr>
<td>gene–environment interaction</td>
<td>97</td>
</tr>
<tr>
<td>longevity</td>
<td>53–54</td>
</tr>
<tr>
<td>mental disorders</td>
<td>97</td>
</tr>
<tr>
<td>gene expression profiling, microarrays in AD</td>
<td>302</td>
</tr>
<tr>
<td>general anaesthesia</td>
<td>817, 820</td>
</tr>
<tr>
<td>mechanism of action</td>
<td>822</td>
</tr>
<tr>
<td>general hospitals</td>
<td>807</td>
</tr>
<tr>
<td>dementia</td>
<td>806, 813</td>
</tr>
<tr>
<td>education/training about psychiatric disorders</td>
<td>804–805</td>
</tr>
<tr>
<td>liaison psychiatry</td>
<td>803–809</td>
</tr>
<tr>
<td>see also liaison psychiatry</td>
<td></td>
</tr>
<tr>
<td>liaison service referrals</td>
<td>807</td>
</tr>
<tr>
<td>psychiatric disorder detection</td>
<td>803–804</td>
</tr>
<tr>
<td>psychiatric disorder prevalence/incidence</td>
<td>803, 804, 807</td>
</tr>
<tr>
<td>see also hospital(s)</td>
<td></td>
</tr>
<tr>
<td>generalized anxiety disorder (GAD)</td>
<td>624</td>
</tr>
<tr>
<td>drug treatment</td>
<td></td>
</tr>
<tr>
<td>benzodiazepines</td>
<td>626</td>
</tr>
<tr>
<td>SSRIs</td>
<td>628</td>
</tr>
<tr>
<td>venlafaxine</td>
<td>628</td>
</tr>
<tr>
<td>see also anxiety disorders</td>
<td></td>
</tr>
<tr>
<td>General Medical Council (GMC), Specialist Register</td>
<td>855</td>
</tr>
<tr>
<td>general paresis of the insane (dementia paralytica)</td>
<td>428</td>
</tr>
<tr>
<td>general practitioners (GPs)</td>
<td>518</td>
</tr>
<tr>
<td>barriers to depression care (ethnic groups)</td>
<td>518, 521</td>
</tr>
<tr>
<td>consultation for depression</td>
<td>525</td>
</tr>
<tr>
<td>ethnic minorities</td>
<td>526</td>
</tr>
<tr>
<td>depression diagnosis</td>
<td>525, 526</td>
</tr>
<tr>
<td>depression management</td>
<td>525, 526</td>
</tr>
<tr>
<td>ethnic groups’ attitudes to seeking help on depression</td>
<td>520–521</td>
</tr>
<tr>
<td>fundholding</td>
<td>747</td>
</tr>
<tr>
<td>perceptions of depression in older people</td>
<td>521</td>
</tr>
<tr>
<td>primary care groups and</td>
<td>747</td>
</tr>
<tr>
<td>services for people with learning disability</td>
<td>692</td>
</tr>
<tr>
<td>sexual problem management</td>
<td>709</td>
</tr>
<tr>
<td>strategies for introducing concept of depression</td>
<td>521</td>
</tr>
<tr>
<td>suicide prevention in elderly people</td>
<td>562</td>
</tr>
<tr>
<td>under-diagnosis of depression</td>
<td>519</td>
</tr>
<tr>
<td>‘general slowing theory’</td>
<td>61</td>
</tr>
<tr>
<td>gene therapy</td>
<td>330–341</td>
</tr>
<tr>
<td>applications</td>
<td>337–338</td>
</tr>
<tr>
<td>cancer trials</td>
<td>336</td>
</tr>
<tr>
<td>CNS, vectors</td>
<td>336</td>
</tr>
<tr>
<td>ex vivo</td>
<td>334</td>
</tr>
<tr>
<td>in vivo</td>
<td>334</td>
</tr>
<tr>
<td>SCID</td>
<td>335</td>
</tr>
<tr>
<td>targets for trials</td>
<td>333</td>
</tr>
<tr>
<td>two-gene trial</td>
<td>337</td>
</tr>
<tr>
<td>vectors</td>
<td>335–336</td>
</tr>
<tr>
<td>genetic factors (aetiological)</td>
<td></td>
</tr>
<tr>
<td>depression</td>
<td>619</td>
</tr>
<tr>
<td>mania</td>
<td>573–574</td>
</tr>
<tr>
<td>obsessive-compulsive disorder</td>
<td>633</td>
</tr>
<tr>
<td>personality disorders</td>
<td>650</td>
</tr>
<tr>
<td>suicidal behaviour</td>
<td>559</td>
</tr>
<tr>
<td>genetic investigations</td>
<td>127</td>
</tr>
<tr>
<td>Genetic Nondiscrimination Act of 2008 (GINA)</td>
<td>410</td>
</tr>
<tr>
<td>genetics</td>
<td></td>
</tr>
<tr>
<td>affective disorders</td>
<td>460–463</td>
</tr>
<tr>
<td>bipolar disorder</td>
<td>461</td>
</tr>
<tr>
<td>of ageing</td>
<td>51–54</td>
</tr>
<tr>
<td>ageing biology</td>
<td>see ageing biology</td>
</tr>
<tr>
<td>environmental/dietary interactions</td>
<td>53–54</td>
</tr>
<tr>
<td>evolutionary influences</td>
<td>51</td>
</tr>
<tr>
<td>mental disorder causation</td>
<td>97</td>
</tr>
<tr>
<td>reactive oxygen species and DNA damage</td>
<td></td>
</tr>
<tr>
<td>Alzheimer’s disease</td>
<td></td>
</tr>
<tr>
<td>see Alzheimer’s disease</td>
<td></td>
</tr>
<tr>
<td>disease</td>
<td></td>
</tr>
<tr>
<td>delirium pathophysiology</td>
<td>197</td>
</tr>
<tr>
<td>Down syndrome</td>
<td>281</td>
</tr>
<tr>
<td>genetic tests</td>
<td></td>
</tr>
<tr>
<td>Alzheimer’s disease</td>
<td>245–246</td>
</tr>
<tr>
<td>ethics and confidentiality</td>
<td>127</td>
</tr>
<tr>
<td>Geriatric Depression Scale (GDS)</td>
<td>142, 152–156, 392, 497, 569</td>
</tr>
<tr>
<td>administration and scoring</td>
<td>152</td>
</tr>
<tr>
<td>alternative forms</td>
<td>153–154</td>
</tr>
<tr>
<td>collateral forms (CS-GDS)</td>
<td>153–154</td>
</tr>
<tr>
<td>depression prevalence in Africa</td>
<td>485</td>
</tr>
<tr>
<td>depression prevalence in Asia</td>
<td>483</td>
</tr>
<tr>
<td>depression prevalence in Europe</td>
<td>480</td>
</tr>
<tr>
<td>development</td>
<td>152</td>
</tr>
<tr>
<td>different ethnic groups</td>
<td>714</td>
</tr>
<tr>
<td>dimensionality</td>
<td>153</td>
</tr>
<tr>
<td>family caregiver assessment</td>
<td>416</td>
</tr>
<tr>
<td>GDS-5 (5 items)</td>
<td>153</td>
</tr>
<tr>
<td>GDS-15 (15 items)</td>
<td>153, 154</td>
</tr>
<tr>
<td>nursing home form</td>
<td>153</td>
</tr>
<tr>
<td>psychometric properties</td>
<td>152–153</td>
</tr>
<tr>
<td>reliability and validity</td>
<td>152–153</td>
</tr>
<tr>
<td>self-rating format</td>
<td>152</td>
</tr>
<tr>
<td>Short form (GDS-SF)</td>
<td>153</td>
</tr>
<tr>
<td>use with special populations/groups</td>
<td>154</td>
</tr>
<tr>
<td>geriatricians, collaboration with</td>
<td>7–8</td>
</tr>
<tr>
<td>Geriatricians Loan Forgiveness Act (2009, US)</td>
<td>774</td>
</tr>
<tr>
<td>geriatric medicine</td>
<td>810</td>
</tr>
<tr>
<td>curative and supportive approaches</td>
<td>810, 814</td>
</tr>
<tr>
<td>psychometric properties</td>
<td>153</td>
</tr>
<tr>
<td>reliability and validity</td>
<td>153</td>
</tr>
<tr>
<td>self-rating format</td>
<td>152</td>
</tr>
<tr>
<td>South Asia</td>
<td>731</td>
</tr>
<tr>
<td>Geriatric Mental State (GMS)</td>
<td>174, 720</td>
</tr>
<tr>
<td>Geriatric Mental State-Automated Geriatric Examination for Computer-Assisted Taxonomy see GMS-AGECAT</td>
<td></td>
</tr>
<tr>
<td>geriatric partial hospital programmes (US)</td>
<td>799–801</td>
</tr>
<tr>
<td>geriatric psychiatrists</td>
<td>751</td>
</tr>
<tr>
<td>career choice</td>
<td>860</td>
</tr>
<tr>
<td>for elderly offenders</td>
<td>696, 698</td>
</tr>
<tr>
<td>ethnic groups (UK)</td>
<td>860</td>
</tr>
<tr>
<td>home assessment by</td>
<td>9, 9, 750, 750</td>
</tr>
<tr>
<td>income in US</td>
<td>779</td>
</tr>
<tr>
<td>number in UK</td>
<td>8, 854</td>
</tr>
<tr>
<td>number in US</td>
<td>779, 857, 858</td>
</tr>
<tr>
<td>decline and reasons for</td>
<td>857</td>
</tr>
<tr>
<td>incentives to increase</td>
<td>858</td>
</tr>
<tr>
<td>recruitment strategies</td>
<td>858</td>
</tr>
<tr>
<td>‘pioneers’ in UK</td>
<td>861</td>
</tr>
<tr>
<td>private see private practice (US)</td>
<td></td>
</tr>
<tr>
<td>in private psychiatric hospitals (US)</td>
<td>797</td>
</tr>
<tr>
<td>role in long-term care in US</td>
<td>790–791</td>
</tr>
<tr>
<td>see also long-term care in US</td>
<td></td>
</tr>
<tr>
<td>role in UK</td>
<td>862</td>
</tr>
<tr>
<td>satisfaction from work</td>
<td>858</td>
</tr>
<tr>
<td>shortage in US</td>
<td>791, 857</td>
</tr>
<tr>
<td>training see training</td>
<td></td>
</tr>
<tr>
<td>workload in UK</td>
<td>751</td>
</tr>
<tr>
<td>workload in US</td>
<td>779</td>
</tr>
<tr>
<td>geriatric psychiatry</td>
<td>751, 788</td>
</tr>
<tr>
<td>concerns over in UK</td>
<td>854</td>
</tr>
<tr>
<td>consultant number in UK</td>
<td>854</td>
</tr>
<tr>
<td>dementia as superspecialty</td>
<td>862</td>
</tr>
<tr>
<td>development/growth as specialty</td>
<td>854</td>
</tr>
<tr>
<td>see also geriatric psychiatry development (UK)</td>
<td></td>
</tr>
<tr>
<td>education</td>
<td>814</td>
</tr>
<tr>
<td>future developments</td>
<td>861–862</td>
</tr>
<tr>
<td>history see history</td>
<td></td>
</tr>
<tr>
<td>of geriatric psychiatry inpatient units</td>
<td>788</td>
</tr>
<tr>
<td>see also hospital(s); medical psychiatric inpatient unit</td>
<td></td>
</tr>
<tr>
<td>Medicare code approval</td>
<td>779, 858</td>
</tr>
<tr>
<td>overlap with medical/neuropsychiatry</td>
<td>788</td>
</tr>
<tr>
<td>research see research</td>
<td></td>
</tr>
<tr>
<td>service development</td>
<td>861–862</td>
</tr>
<tr>
<td>service provision</td>
<td>860–861</td>
</tr>
<tr>
<td>in England see geriatric psychiatry services (England)</td>
<td></td>
</tr>
<tr>
<td>subspecialty recognition</td>
<td>861</td>
</tr>
<tr>
<td>training duration</td>
<td>854</td>
</tr>
<tr>
<td>WHO consensus statements</td>
<td>860, 861</td>
</tr>
<tr>
<td>geriatric psychiatry development (UK)</td>
<td>7–11, 854</td>
</tr>
<tr>
<td>clinical innovation</td>
<td>9</td>
</tr>
<tr>
<td>coordination by central body</td>
<td>8</td>
</tr>
<tr>
<td>core features of service (2009)</td>
<td>9</td>
</tr>
<tr>
<td>funding for research</td>
<td>8</td>
</tr>
<tr>
<td>geriatrician collaboration</td>
<td>7–8</td>
</tr>
<tr>
<td>government initiatives</td>
<td>9–10</td>
</tr>
<tr>
<td>long stay care</td>
<td>9, 751</td>
</tr>
<tr>
<td>organizations involved in</td>
<td>8</td>
</tr>
<tr>
<td>pioneering services</td>
<td>8</td>
</tr>
<tr>
<td>post–during World War II</td>
<td>7</td>
</tr>
<tr>
<td>psychiatrist collaboration</td>
<td>8</td>
</tr>
<tr>
<td>research and academic development</td>
<td>8</td>
</tr>
<tr>
<td>resources</td>
<td>8</td>
</tr>
<tr>
<td>teaching and training</td>
<td>8–9, 814, 854</td>
</tr>
<tr>
<td>see also training</td>
<td></td>
</tr>
<tr>
<td>psychogeriatric services (England)</td>
<td></td>
</tr>
<tr>
<td>geriatric psychiatry inpatient unit see hospital(s); private psychiatric hospitals (US)</td>
<td>797</td>
</tr>
<tr>
<td>geriatric psychiatry inpatient unit nurse</td>
<td>797</td>
</tr>
</tbody>
</table>
SUBJECT INDEX

risk with oral hypoglycaemics 59
hypergonadism 708
hypomania, classification 457
hypometabolism (cerebral), effects 259
hyperperfusion, chronic (cerebral), depression and 468
hypopnoeas 703
hypotension
postural see orthostatic hypotension role in postoperative cognitive dysfunction 818, 820
hypothalamic neurons, decline with age 45
hypothalamic-pituitary-adrenal (HPA) axis 47
AD risk and 273
depression and 470
hypothalamic suprachiasmatic nucleus (SCN) 48
hypothalamus, melatonin receptors 48
hyperthermia, anaesthetic effect on tau proteins and 822
hypothyroidism 384, 723
lithium-induced 581
primary 47
hypoxaemia, role in postoperative cognitive dysfunction 818, 820
hysteria 636
IAPT (Improving Access to Psychological Services) 7, 527, 549
ICD-6 640
ICD-8
neurotic disorders 611
reaction to severe stress 640
ICD-9 105, 203
neurotic disorders 611
post-traumatic stress disorder 641
psychotic disorders 592
acute stress reaction 640
adjustment disorder 459, 642
bipolar disorder 458
dementia 201–202, 203, 208
as ‘organic’ disorder 202
types and classification 105–106
depression 457–458
prevalence in America 482
prevalence in Asia 483
DSM-IV differences 107
F0 section 106
ICD-9 comparison 105
limitations 107
mood disorders 457–459
multi-axial coding 106
neurotic disorders 611–612, 614
omission of reference to age 106
‘organic’ and ‘symptomatic’ criteria 105, 107
post-traumatic stress disorder 641
somatoform disorders 636
uses and objectives 105
vascular dementia 342
versions 105
ICD-10-DCR 105, 106
ICD-11 107, 108
psychotic disorders 591, 592
Identity Process Theory 650
illicit drugs, misuse 680, 681
illness contingency planning 841
illusions 114–115, 230
imaging see neuroimaging
imipramine, depression in Parkinson’s disease 475
immortalized cell lines 335
immunological effects, of caregiving 831
immunological investigations 124
immunotherapy, Alzheimer’s disease 309
IMPACT study 99, 398, 526, 546
impairment 66
Improving Access to Psychological Services (IAPT) 7, 527, 549
Improving Mood, Promoting Access to Collaborative Care Treatment (IMPACT) 99, 398, 526, 546
inappropriate secretion of antidiuretic hormone (SIADH) 538
incapacity see mental incapacity incidence, definition 207
cost-effectiveness ratio (ICER) 91
Independent Living Skills Survey (ILSS) 179, 180
Independent Mental Capacity Advocate (IMCA) 853
Independent Mental Health Advocate (IMHA) 852
identermediate sentences 851
India
dementia prevalence 720
population pyramids and changing distribution 85
Indianapolis–Ibadan Dementia Research 734
induced pluripotent stem cells (iPSC) 334, 335
transplantation 334–335
infections, mania aetiology 574
inflammation 407
in Alzheimer’s disease 300–301
delirium pathophysiology 196–197
vascular disease and depression link 470
informal care, economic aspects 91–92
Informant Questionnaire on Cognitive Impairment (INQCODE) 411
independent consent 411
ECT 533
see also consent
inhalational anaesthetics 822
inositol triphosphate (IP3) 292
inpatient units see hospital(s); medical psychiatric inpatient unit; psychogeriatric services (England)
insecticides, suicide in China 739
insight 115
lacking in dementia 412
lacking in FTD 348
in Mental State Examination (MSE) 115
reduced in Alzheimer’s disease 228
insomnia 700–702
in Alzheimer’s disease 230, 703
causes 701
co-morbid 701
complementary and alternative medicine 701–702
epidemiology 700, 701
evaluation 701
management 640–641
nocturnal 230
non-pharmacological treatment 701
pharmacological treatment 701
secondary 701
Institute of Medicine (IOM) 774, 779, 844, 858
Institute on Aging (IOA) (USA) 423, 425
institutional abuse 835
institutional care
caregiver’s decision about 831–832
postponement, as outcome in economic analyses 94
types of institutions 99
see also care homes; long-term care; nursing homes
instructional advance directives 411
instrumental activities of daily living (IADLs) 177
alcohol abuse effect 675
rating 177
Instrumental Activities of Daily Living Scale (IADL) 179, 180
insulin
receptors 272
resistance 47, 470, 723
SIRT1 gene effect 52
insulin degrading enzyme (IDE) 293
insulin/IGF-1 signalling 53
downregulation, progeroid mice 52
insulin-like growth factor 1 (IGF-1) 46, 52
intellectual functioning
assessment 390, 391
lifelong optimal level, prediction 138
see also cognition/cognitive abilities
intelligence
assessment tests 135, 137–138, 390, 391
effect on neuropsychological assessment 234
interfering RNA (RNAi) 336–337
INTERHEART study 723
interleukin-6 (IL-6) 282
intermediate care 8, 750, 813
internal coherence 767, 768
‘Internal Market’ 746, 749
International Classification of Diseases see entries beginning ICD
International Classification of Functioning, Disability and Health (ICF) 811
International Conference on Alzheimer’s Disease (ICAD) 861
International Journal of Geriatric Psychiatry 8
International Late-Onset Schizophrenia Group 592, 593
International Longevity Center 423, 425
International Personality Disorders Examination (IPDE) 655
International Psychogeriatric Association (IPA) 860
International Study of Postoperative Cognitive Dysfunction (ISPOCD) 818–821
magnetization transfer imaging, depression (geriatric) 491

magnetization transfer ratio (MTR), depression (geriatric) 491

magnetoencephalography (MEG) rhythms in AD 38–39

normal ageing 38

Maintenance Therapies for Late Life Depression (MTLLD1 and MTLLDII) trials 547–548

major depression see depression (geriatric), major

malabsorption, alcohol abuse and 666

malnutrition 824

alcohol abuse contributing to 666 in hospitals and care homes 824 management 826 mental illness and 825 physical/mental consequences 824 prevention 825–826 risk groups 824, 825 in UK, USA, Australia 824

Malnutrition Universal Screening Tool 825

managed care companies 778, 782

managed care programmes 770, 771, 778, 782

mania 576–588, 600

crude, treatment 580–582

age of onset 576–577

bi-modality in age of onset 573

clinical features and health service usage 579

cognitive impairment 578–579 in dementia 574 early- vs late-onset 574

ECT 531

epidemiology 573, 576, 600

late-onset 500

treatment 539

management 580–583

mortality 576

neuromaging 578

pathogenesis 579

rapid cycling 458

right-sided lesions and 578

risk factors 573–574 secondary 574, 576, 578

speech in 113

stroke association 574

subcortical hyperintensities 574

unipolar 577

vascular subtype 578, 579

see also bipolar disorder

manic episodes

classification 457

irritable/angry 457

MAOIs see monoamine oxidase inhibitors (MAOIs)

MAPT see microtubule-associated protein tau (MAPT)

MAPT gene

knock-out mice 254

mutations 240, 353

marital status, depression prevalence 618

masturbation 709

Maudsley Hospital 12, 13

MCI see mild cognitive impairment (MCI)

McLean Hospital (Massachusetts, USA) 798, 799, 800

discharge diagnosis 800

partial hospital programme 800–801

meals, presentation and supervision 825

means-testing 750, 751, 759

Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) 176

medial parietal region, deactivation (fMRI) for memory encoding 439

changes in AD 440

changes in MCI 440

medial temporal lobe (MTL)

fMRI activity decreased in AD 439–440 memory function 439

normal ageing 439

suppression in normal memory encoding 440

hyperactivation

Alzheimer’s disease 440

mild cognitive impairment 441, 442

hypoaivation, in mild cognitive impairment 441, 442

volume reduction in AD 17

Medicaid (US) 770

beneficiaries and expenditures 772

expenditure on home/community-based services 773

expenditure on nursing homes 773

dually eligible Medicare beneficiaries with 771–772

expenditure on schizophrenia 774

medical history 117

‘Medical Home’ (US) 773

medical hospitals see general hospitals

medical insurance 745

US 782

see also Medicaid (US); Medicare (US)

‘medically unexplained symptoms’ 636

clinical presentation 637

general hospitals 806–807 management approach 638–639

prevalence 637

treatment 639

see also somatoform disorders

Medical Outcomes Study (MOS), SF-36 179, 180

medical psychiatric inpatient unit (US) 785–789

administration 785–788

admission criteria/priority system 786

clinical programming 787

daily schedule/programme 787

design/structure/layout 785–786

factors influencing re-admission 788

factors influencing stay duration 788

unit operations 787

clinical issues 789–789

inpatient evaluation/management 788–789

inappropriate admissions to 786

multidisciplinary team 786–787, 788, 789

administration 785–788

admission criteria/priority system 786

clinical programming 787

daily schedule/programme 787

design/structure/layout 785–786

factors influencing re-admission 788

factors influencing stay duration 788

unit operations 787

clinical issues 789–789

inpatient evaluation/management 788–789

inappropriate admissions to 786

multidisciplinary team 786–787, 788, 789

Lund study continued

population and years studied 222

Lund Longitudinal Dementia study 300

luteinizing hormone (LH) 46

elevation, in AD 47

Lyme disease 427–428

investigations 427

treatment 428

MacArthur Foundation 70, 71

macrostructural changes, normal ageing 17, 36

macular degeneration 845

madhouses 745

MADRS see Montgomery Asberg Depression Rating Scale (MADRS)

magnetic resonance imaging (MRI) 125, 435

1.5T, 3T vs 7T image differences 434

alcoholic dementia 379

Alzheimer’s disease 301

bipolar disorder 578

brain volume reductions, depression 489–490

CJD 375

cortical thickness mapping 262

cryptococcosis (CNS) 430

depression 489–490, 490–491

echo time (TE) 434

‘fluid void’ sign 125

frontotemporal dementia 350, 351

functional see functional MRI (fMRI)

microstructural white-matter lesions 490–491

normal ageing

iron/ferritin accumulation 21–22

macrostructural changes 17

structural–functional correlations 17

perfusion 435

principles and technique 434

proton 446, 447

repetition time (TR) 434

structural 434

T1 and T2 relaxation times 434

vascular depression 468

white matter lesions 344

magnetic resonance spectroscopy (MRS) 446–454

31P-MRS 446, 448

in depression 449–450

Alzheimer’s disease 450–451

bipolar disorder 449, 450

depression (geriatric) 448–450, 492

frontotemporal dementia 451

Lewy body dementia 451

mild cognitive impairment 450

normal ageing 446–448

nuclear isotopes used 446

principles 446

proton see proton magnetic resonance spectroscopy

strengths and limitations 451

two-dimensional 451

vascular dementia 451

magnetization transfer imaging, depression (geriatric) 491

SUBJECT INDEX
neuropsychiatric effects 307–308, 319
prescribing and monitoring 307
rational and cognitive effects 307
side effects 305, 307, 314
memapsin see BACE1
memories of adolescence/young adulthood 62
flashbulb 62
memory 397
age-related decline 61–62
assessment 131, 138, 390, 391
consolidation, impairment in AD 393
cueing, failure to benefit in AD 393
decorative 397
deficits see memory impairment/deficits
encoding, medial/lateral parietal region
deactivation 439
episodic see episodic memory
formation
adult neurogenesis role 332
medial temporal lobe activation 439
levels of processing approach 397
long-term 226, 390
neural networks supporting 439
non-declarative 397
procedural, training 326
processing, reduced depth, with age 61
prospective 62
recall, Alzheimer’s disease 226, 393
retention, assessment 390
self-perception 397
semantic see semantic memory
training see memory training
types 138, 397
working see working memory
memory books 326
memory clinics 8
memory clues 226
memory disorder clinics 801
Memory Fitness programme 399
memory group therapy 798
memory impairment/deficits
age-related decline 17, 61–62
alcohol misuse and 111
Alzheimer’s disease 17, 204, 226, 393
impaired neurogenesis and 291
Aβ misfolding and oligomerization and
290–291
dementia 233
dissociative amnesia vs 643
dementia, anemic syndrome and delirium
center 107
dementias not presenting with 204, 208
depression 394
ECT side effect 533
general slowing theory and 61
herpes simplex encephalitis and 431
history-taking 110
normal aging 17
as presenting complaint 129
recall/use old vs new information 62
SPECT imaging 257–258
memory improvement
complementary/alternative medicine see
complementary and alternative
medicine (CAM)
culturally based healing arts 405–406
diet/nutritional supplements 404
herbal preparations 403–404
SAMe 404–405
see also memory training
memory training 397–402
AD management 326
approaches 398
biofeedback 406, 407
computer-assisted interventions 398–399
factors influencing 398
long-term outcomes 399
multifactorial programmes 399
pretraining 398
see also cognitive training
men
age-related hormonal changes 706
sexual disorders 708
meningioma 386
meningitis
HSV 429
tuberculous 426
menopause 46, 406
mental abilities see cognition/cognitive
abilities
mental capacity
investigations and legal issues 127
lack, decision-making 767, 769
see also mental incapacity
Mental Capacity Act (2005) 10, 746, 761,
841, 842, 852–853
development 851
on investigations/testing 127
principles 852
mental deterioration in elderly, 19th century
views 4
mental disorders
adverse outcome potential in long-term
care 795
ageing not associated with increased risk 97
definition, Mental Health Act 2007 852
in Down syndrome 283
emotional distress distinction 97
genetic and social causes 97–98
importance of sense of purpose 98
learning disability with 689
malnutrition and 825–826
importance of sense of purpose 98
religion/spirituality benefits 98
religion/spirituality benefits 98
risk indicators 847
social causation 97–98
social selection 97, 98
somatoform presentation 638
treatment 638
treatment, shaped by social factors 99
mental health 717
assessment, ethnic groups 713
economics see health economics
in family caregivers 830–831
interventions, goal 176
prevalence changes 88
problems in primary care 524
### SUBJECT INDEX

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alzheimer’s disease diagnosis</td>
<td>238</td>
</tr>
<tr>
<td>in CFAS I/II study</td>
<td>216</td>
</tr>
<tr>
<td>Chinese version</td>
<td>737</td>
</tr>
<tr>
<td>criticisms of</td>
<td>141</td>
</tr>
<tr>
<td>extended, in CFAS I/II study</td>
<td>216</td>
</tr>
<tr>
<td>FAST relationship</td>
<td>166</td>
</tr>
<tr>
<td>Global Deterioration Scale (GDS) comparison</td>
<td>162</td>
</tr>
<tr>
<td>Global Deteriation Scale (GDS) relationship</td>
<td>165</td>
</tr>
<tr>
<td>inter-rater reliability</td>
<td>142</td>
</tr>
<tr>
<td>IQCODE comparison</td>
<td>148, 149</td>
</tr>
<tr>
<td>limitation of education level</td>
<td>734</td>
</tr>
<tr>
<td>low scores, conditions associated</td>
<td>145</td>
</tr>
<tr>
<td>recommendations on</td>
<td>145</td>
</tr>
<tr>
<td>reliability and validity</td>
<td>145–146</td>
</tr>
<tr>
<td>revision (MMSE2)</td>
<td>146</td>
</tr>
<tr>
<td>standardized with normative values</td>
<td>145</td>
</tr>
<tr>
<td>minimum data set (MDS)</td>
<td>793</td>
</tr>
<tr>
<td>Ministry of Health for England and Wales</td>
<td>745</td>
</tr>
<tr>
<td>Minnesota Multiphasic Personality Inventory (2)</td>
<td>392</td>
</tr>
<tr>
<td>mirtazapine</td>
<td>57</td>
</tr>
<tr>
<td>anxiety/anxiety disorders</td>
<td>628</td>
</tr>
<tr>
<td>depression in Parkinson’s disease</td>
<td>475</td>
</tr>
<tr>
<td>misidentification syndromes, Alzheimer’s disease</td>
<td>229</td>
</tr>
<tr>
<td>mitochondrial DNA</td>
<td>29</td>
</tr>
<tr>
<td>mutation accumulation</td>
<td>53</td>
</tr>
<tr>
<td>mitochondrial dysfunction, in thiamine deficiency</td>
<td>379</td>
</tr>
<tr>
<td>mitochondrial oxidative phosphorylation, thiamine role</td>
<td>379</td>
</tr>
<tr>
<td>mixed anxiety and depressive disorder</td>
<td>612</td>
</tr>
<tr>
<td>mixed dementia</td>
<td>345</td>
</tr>
<tr>
<td>see also Alzheimer’s disease (AD); vascular dementia (VaD)</td>
<td></td>
</tr>
<tr>
<td>mnemonic strategies</td>
<td>398</td>
</tr>
<tr>
<td>mobility, maintaining, NHS continuing care</td>
<td>763</td>
</tr>
<tr>
<td>moclobemide</td>
<td>537</td>
</tr>
<tr>
<td>depression in Parkinson’s disease</td>
<td>475</td>
</tr>
<tr>
<td>Modernising Medical Careers (2004, UK)</td>
<td>854</td>
</tr>
<tr>
<td>Modification of Diet in Renal Disease (MDRD) study</td>
<td>57</td>
</tr>
<tr>
<td>Moloney murine leukaemia virus (MMLV)</td>
<td>336</td>
</tr>
<tr>
<td>Monitor (Foundation Trust monitoring)</td>
<td>747</td>
</tr>
<tr>
<td>monoamine oxidase inhibitors (MAOIs)</td>
<td>537</td>
</tr>
<tr>
<td>anxiety/anxiety disorders</td>
<td>628</td>
</tr>
<tr>
<td>MAOA inhibitor</td>
<td>475</td>
</tr>
<tr>
<td>OCD treatment</td>
<td>634</td>
</tr>
<tr>
<td>side effects</td>
<td>628</td>
</tr>
<tr>
<td>treatment-resistant depression</td>
<td>540</td>
</tr>
<tr>
<td>tyramine-rich foods interaction</td>
<td>537</td>
</tr>
<tr>
<td>monoclonal 3F4 antibodies</td>
<td>373</td>
</tr>
<tr>
<td>Montessori-based activities</td>
<td>325</td>
</tr>
<tr>
<td>Montgomery Asberg Depression Rating Scale (MADRS)</td>
<td>154, 497, 569</td>
</tr>
<tr>
<td>cross-cultural validity</td>
<td>718</td>
</tr>
<tr>
<td>mood</td>
<td></td>
</tr>
</tbody>
</table>
assessment tests 392
depressed but not disordered 459
in Mental State Examination (MSE) 114
symptoms in AD 227–228
mood disorders
adjustment disorder with depressed mood
459
age of onset 460
in Alzheimer’s disease 227–228, 324
bipolar see bipolar disorder
causes 509
classification 457–459
dysthymia, classification 458–459
early-onset, genetic causes 461
ECT for 529–530
genetics 460–463
age-related variation, reasons 460
bipolar disorder 461
depression 461
increased phenocy expression with age 460
late-life 460–461
multifactorial inheritance 460
in Parkinson’s disease see Parkinson’s
disease (PD)
recurrent 458
secondary 458
substance-induced 566
treatment, in medical psychiatric inpatient unit 788
see also bipolar disorder; depression (geriatric); mania
mood stabilizers
acute mania 580–581
Alzheimer’s disease 320
dosage and side effects 314
bipolar disorder 582, 583
monitoring (serum levels) 126
moral dilemmas 766–767
morals, practical application 766–768
morbidity, compression 67
morphine
metabolites 56
pharmacodynamics 58
motor-evoked potentials (MEPs) 37
motor neuron disease (MND) 349
motor threshold, reduced in AD 37
mouse models
Alzheimer’s disease 252–256, 272
3XTg 292
advantages 255
APLP2 knockout 289
APP-deficient 289
APP-swe 252, 253
CaMKIIα-tTA x tet-APPswe/ind 253, 254
conditional transgenic mice 253, 254
‘congenic’ strain 255
double transgenic mice 253
knockout 254
limitations 255
PDAPP model 252, 253, 272
PSEN1 mutations 242, 252
rTG3696AB 254
rTg4510 253, 254
Tg2576 272
triple transgenic mice 253
variability 255
knockin, PSEN1 mutations 242
knock-out 254
APP 289
BACE1 254, 290
MAPT gene 254
PSEN1 mutations 242
mutations with altered life span 52
reduced DNA repair 52
transgenic 272
age-dependent behavioural deficits 255
amyloid beta (Aβ) amyloidosis 252, 254–255, 291
conditional 253, 254
tauopathy 252–253
triple 253, 254
movement, abnormal, in physical examination 118
movement disorders, sleep-related 702
[18F]MPPF-PET 260
MRI see magnetic resonance imaging (MRI)
MRS see magnetic resonance spectroscopy (MRS)
MTLDD1 and MTLDDLII trials 547–548
Multidimensional Observation Scale of Elderly Subjects (MOSES) 179, 181
multidisciplinary team 753
community mental health teams 756
medical psychiatric inpatient unit 786–787
new ways of working by 756
private psychiatric hospitals (US) 797
in psychogeriatric services 750
in rehabilitation 811
team members 753
medical psychiatric inpatient unit 786–787
multifocal arteriosclerotic dementia 4
multi-infarct dementia 4
multifocal arteriosclerotic dementia 4
Multilingual Aphasia Exam 391
multiple jeopardy concept 524
Multilingual Aphasia Exam 391
myocardial infarction 619
ECT cautions 531
silent 614
myoclonus 133
in CJD 377
myo-inositol
abnormal levels, predementia phase 282
Down syndrome and 282
magnetic resonance spectroscopy 446
increased in AD 450
increased in depression 448
increased in diabetes 448–449
mild cognitive impairment 450
normal ageing 447
NAA (N-acetylaspartate), magnetic resonance spectroscopy 446
depression 448, 449, 492
mild cognitive impairment 450
in normal ageing 447
lithium effect in bipolar disorder 583
naltrexone, in alcohol abuse 668
names, difficulty remembering 398, 439
naming tests 131, 132
napping 701
National Alliance for Caregiving 423, 424
National Alliance for the Mentally Ill (NAMI) 787
National Alzheimer’s Coordinating Center (NACC) 422, 423
National Association of Area Agencies on Aging (n4a) 422, 424
National Cell Repository for Alzheimer’s Disease (NCRAD) 422, 423
National Center on Caregiving (NCC) 424
National Council on Aging (NCOA) 423, 425
National Dementia Strategy (UK) 9–10, 751, 812, 813
aims/criteria 814
National Diet and Nutrition Survey (UK) 824, 825
National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) 577, 671, 672, 673, 675, 676
National Family Caregivers Association (NFCA) 422, 423
National Health and Nutrition Surveys (US) 824
National Health Service (NHS) 7, 746
beds occupied by elderly people 803
bureaucracy 748
continuing care see NHS continuing care establishment 746
funding 747–748
geriatric psychiatrists role 862
internal market 746, 749
long-term care in dementia 749–750
malnutrition in hospitals 824
market forces and competition 746–747, 749
Next Stage Review 748
psychogeriatric services 749, 751
reforms (1974–1980s) 746
reforms (1997–2007) 747–748
Neurology (NIMHE) 774
National Institute for Aging (NIA) (USA) 421, 422, 857
National Institute on Alcohol Abuse and Alcoholism (NIAAA) 673
National Institute for Health and Clinical Excellence (NICE) see NICE
National Institute of Mental Health (NIMH) 774
National Institute for Mental Health in England (NIMHE) 741
National Performance Framework 747
National Service Framework for Older People 59, 518, 525, 747, 854
key components 756
National Service Frameworks 751
National Survey of Psychiatric Morbidity (UK) 620
SUBJECT INDEX 895
malnutrition in hospitals 824
neuroendocrinology 45–50
neuritic plaques 287
neurite growth inhibitor (NOGO) 290
neurasthenia 613, 643–644, 739
neural stem cells (NSCs) 43, 291, 330, 332–334
neural reserves, AD risk 272
neural repair 330, 337–338
Netherlands
nerve growth factor (NGF) 42, 331
neprilysin 288, 309
NEO Personality Inventory 650, 655
neocortex, cholinergic innervation, loss in Alzheimer's disease 295
neocortex, dementia association 218
clinical features and differential diagnosis
see also neural stem cells (NSCs)
neurochemistry
neurocognitive functioning, patterns in normal ageing 447
neurocognitive disorders 107
neurocognitive functioning, patterns in dementia 233–234
neurodegenerative disorders
CJD see Creutzfeldt–Jakob disease (CJD) classification 108
early detection, neuropsychological assessment trends 235
functional changes 29–30
individual variability and overlaps 108
neuroendocrinology 45–50
vascular disease and depression 470
neurofeedback, cognitive enhancement 406
neurofibrillary tangles 36, 287
age-related cognitive decline link 259, 295
Alzheimer’s disease 240
treatment target 309
conditional tau transgenic mice 253, 254
Down syndrome 281
entorhinal cortex 295
[18F]FDDNP-PET imaging 259 in MCI 295
neocortex, dementia association 218
see also tau, hyperphosphorylation
neurofilamentopathies 108
neurogenesis 331–334
adult 43, 330, 332
background to 331–332
role in memory formation 332
sites 291, 332
cross-talk and effects 291
decline with age 291, 333
embryonic/postnatal, PS1 regulating 291
hippocampal 333, 334
impairment in AD 291, 334
psychiatric illness and 333
stroke and 334
see also neural stem cells (NSCs)
neurogenis signalling, PS1 role 291
neurogenic cell niche 330, 332
cell types (A/G, B, C/D) 332
compartments 332
function 332
neurodegenerative disease 333–334
normal ageing 333
regulation 332–333
subventricular zone, impaired olfaction and 334
see also neural stem cells (NSCs); neurogenesis
neurohypophysis 47–48
neuroimaging 233, 490
alcoholic dementia 379
Alzheimer’s disease 301
cognitive ability decline studies 62
delirium 196
dementia diagnosis 125, 602
impact on epidemiology studies 211
in learning disability 690
depression 489–494, 496
3D brain mapping technique 490
functional imaging 491–492
methodological issues 490
microstructural imaging 490–491
regions of interest (ROIs) 489
volumetric studies 489–490
white matter hyperintensities 490–491
see also individual techniques
Down syndrome 282–283
functional see functional imaging
IQCODE validation against 149
metabolic/molecular scanning see positron emission tomography (PET); single photon emission computed tomography (SPECT)
normal ageing 438–439
structural
CT 433
normal ageing 17–27
white-matter lesions 344, 490–491
see also diffusion tensor imaging (DTI); magnetic resonance imaging (MRI)
vascular dementia 345
neuroinflammation, Down syndrome 282
neuroleptics see antipsychotic drugs
neurological examination 119–121
in bedside cognitive assessment 133, 137
behavioural variant (bvFTD) 349
importance 119
neuronal intermediate filament inclusion body disease 353
neuronal plasticity 36
see also neurogenesis
neuronal stem cells see neural stem cells (NSCs)
neurons
loss
[18F]MPPF-PET 260
FAST scale relationship 166
locus coeruleus, in AD 299
nucleus of Meynert, in AD 295
regeneration 332, 333
see also neural stem cells (NSCs)
volume decline, in normal ageing 447
neuropathology 287
Alzheimer’s disease 239–240
dementia 218
Down syndrome 281
IQCODE validation against 149
molecular, of AD see Alzheimer’s disease
neurophysiology of ageing (brain) 36–41
cortical excitability 37–38
EEG/MEG rhythms 38–39
transcranial magnetic stimulation studies 37
Neuropsychiatric Inventory (NPI) 227, 312, 313, 392
neuropsychiatric symptom rating scales 312, 313
neuropsychiatric symptoms (cognitive) see attention; cognition/cognitive abilities; executive function; memory; orientation (general)
nuepsychiatric symptoms (non-cognitive) 227
Alzheimer’s disease 226, 227–229
affective disturbances prominence 227–229
cholinesterase inhibitor effect 307–308, 318–319
costs related to 312
management see behavioural management, in AD
mementine effect 307–308, 319
prevalence 228, 229
psychotic disturbance prominence 229–230
Lewy body dementias 364, 365
management in 368–369
see also antipsychotic drugs; behavioural disturbances
normal ageing continued
neurogenic stem cell niche 333
neuroimaging 438–439
neuronal numbers, FAST and 166, 167
quantitative fibre tracking 18–20, 21
tau and tangle pathology 295
white matter structure/function
relationships 21
working memory deficits 17
see also successful ageing
normal pressure hydrocephalus (NPH)
384, 386
gait 130
reversible dementia 385, 386
North America, depression prevalence 480, 482, 483
nortriptyline
after ECT 530
in anxiety/anxiety disorders 628
depression treatment 537, 538
relapse/recurrence reduced by 539
effect on brain function 32
nosology see entries beginning DSM or ICD: specific disorders
NREM sleep 700, 701, 702
nucleoside triphosphate (NTP), in
NREM sleep 700, 701, 702
number-needed-to-treat (NNT) 847
nursing homes 99–100
activities, importance 99–100
admission, assessment at (in US) 793–794
alternatives, in US 773
depression in, prevention 845
drug formularies 780
family disengagement 764
Geriatric Depression Scale (GDS) form for 153
NHS continuing care boundary 760
pain in, prevalence 840
relocating to, effect on family caregivers 831–832
suicidal behaviour in 561
transfer to hospitals before death 841
triggers leading to admission 99
see also care homes
nutrition 764
artificial 826, 827
market-led approach and shopping 825
poor see malnutrition
nutritional deficiencies 825, 826, 827
dementia aetiology 723
management 826
nutritional deprivation
AD risk 274
dementia aetiology 723
nutritional state 824–828
nutritional supplements
AD improvement 301
AD prevention 275
memory enhancement 404
nystagmus 133
obesity 824
AD risk 273
in learning disability 691

mortality risk 65
OBRA '87 see Omnibus Budget Reconciliation Act of 1987 (OBRA-87)
observation
cognitive assessment 129, 130
in Mental State Examination 113
physical examination 118, 119
obsession(s) 114, 129
obsessional personality disorder 632
obsessional thoughts 632
obsessive-compulsive disorder (OCD)
632–635
aetiology 633
age of onset 632
clinical assessment 632
clinical features 632
diagnostic criteria/features 612, 632
differential diagnosis 632
epidemiology 633
late-onset 632
non-pharmacological 633
pharmacological 633–634
physical (ECT) 634
obsessive-compulsive personality disorder, cognitive distortions 650
obstructive sleep apnoea (OSA) 703
obstructive sleep apnoea syndrome (OSAS) 703
occupational therapist, role in private psychiatric hospital 797
occupational therapy, feeding and nutritional aspects 826
Ocimum sanctum 405
oestrogen 46
age-related changes 706
dementia (and AD) prevention 210, 274–275
Down syndrome 282
lack, post-menopausal, effects 46
offenders 694–699
age for considering as ‘elderly’ 694
criminal justice system 696–697
diagnostic considerations 695–696
offence types 694–695
sexual 697, 698
prevention 698
psychiatric services 697
risk assessment 698
treatment 698
olanzapine
adverse effects 313, 581
Alzheimer’s disease 318
dosage 313
psychotic disorders 605
old age 810
definition 616
poverty and ill health associations 745
old age psychiatrists see geriatric psychiatrists
old age psychiatry see geriatric psychiatry
Older Americans Act (OAA) 425
older people
attitudes to 814
definition 616
status in South Asia 731
oldest old
alcohol use 672
demographics 88
depression and physical illness 512
Geriatric Depression Scale use 154
olfaction impairment 334
Olmstead decision 773
omega-3 fatty acids
in depression and vascular disease 470
supplements 404, 407
omega-6 fatty acids 404
Omnibus Budget Reconciliation Act of 1987 (OBRA-87)
770, 792, 812
Interpretive Guidelines 793
specfic psychotropic drugs 794, 795
philosophy 792
opiate addiction, dementia associated 380
opportunity cost 90
opportunity cost approach 91–92
OPTIMA trial 301
oral cavity, examination 120
orbital frontal circuit (OCF), right, mania and 578
orbitofrontal cortex/region
in depression, volume reduction 489
OCD aetiology 633
organic mental disorders
delusional/hallucinatory, schizophrenia vs 600
dementia with 384
DSM-IV not using term 106–107
ICD-10 and 105, 107
incidence
age-/sex-specific 222–223, 224
Lundby study 222, 223, 224
psychiatric origin vs 130
response to treatment, reversible dementia 384–386
treated in private psychiatric hospitals (US) 796
orgasms 706
difficulties in women 709
orientation (general), assessment 389, 391
orientation to time, assessment 131, 389
orthostatic hypotension 58, 628
in examination 119
orthostatic intolerance 58
outcome measures, in health economics analyses 92–93
outpatient psychiatric care (US) 777–784
see also private practice (US)
over-familiarity 113
over-the-counter medication, misuse 680, 681
detection 682
oxidative phosphorylation, reduction, mitochondrial mutations 53
oxidative stress
AD neuropathology 292–293, 308
Down syndrome 282
oxygen-15 28
oxyhaemoglobin 29
oxytocin 48
p53 300
PACE (Programs of All-Inclusive Care for the Elderly) 771
pain
assessment/treatment 763
in delirium 193
in dementia 840
‘total’ 839

paired helical filaments (PHF) 252

palliative care
advance care planning 840–841
definition and goals 838
indications in dementia 839–840
international perspective 838–839
key aims 839
models 839
partnership with 842
people with learning disability 692
principles 839
risk of harm and antipsychotics 839, 840
spiritual support 741, 742
see also end-of-life care

paranoid delirium 600
paranoid delusions, Alzheimer’s disease 229
paranoid disorders 592, 599–603
antipsychotic drugs 604, 605
CBT for 605–606
clinical assessment 601–603
interview and history-taking 601
mental state examination 601
physical examination 602
differential diagnosis 599–601
see also psychotic disorders
paranoid hallucinatory disorders 600
paranoid ideation 599
disorders with, differential diagnosis 599–601
incidence/prevalences 597, 599
of theft 114, 229, 312, 326, 600
paranoid personality disorder 600
cognitive distortions 650
paranoid states, mood-incongruent 596–598
paranoid symptoms
clinical assessment 601–603
differential diagnosis 599–601
schizophrenia 599
paraphrenia 591, 592, 596
ECT in 531
late 596, 598, 599
parasomnia 702

parkinsonism
in behavioural variant (bvFTD) 349
in Parkinson’s disease dementia 364, 365
management 369
Parkinson’s disease (PD)
age of onset 473
cognitive impairment, personality disorders vs 657
dementia see Parkinson’s disease (with) dementia (PDD)
depression 473–478, 552, 567
aetiology 474
cognitive impairment relationship 474
diagnosis 473, 567
ECT therapy 475, 531
epidemiology 473–474
factors affecting treatment 477
management 474–477, 567
as premorbid sign 473–474
rating scales 473
screening 476, 477
‘gait’ 604
Lewy bodies 360
mood disorders 473–478
morality 474
neural transplants 331
non-motor symptoms 473
palliative care 838
prevalence 473
as a proteinopathy (α-synuclein) 377
psychosis 600
risk factors, antidepressant therapy and 474
severity, depression relationship 474
subventricular zone thinning 334
α-synuclein mutation 127
tremor 133
visual hallucinations 600
Parkinson’s disease (with) dementia (PDD)
360
brain functional changes 30
classification 361
clinical diagnosis 366
clinical features 361, 364–366
differential diagnosis 366
DLB 363
epidemiology 208, 364
investigations and biomarkers 366–367
management 368, 369
possible, diagnosis 361, 362
probable, diagnosis 361, 362
risk factors 364
see also Lewy body dementias
paroxetine
in depression 538, 539
side effects 628
PASA (posterior-anterior shift in ageing) 29
phenomenon
passivity phenomena 114
pathological laughing 578
Patient Reported Outcomes Measurement Information System (PROMIS) 176
penile stimulation 706–707
pensions 745
pentosan polysulphate (PPA), in CJD 376
perception, in Mental State Examination (MSE) 114–115
percutaneous endoscopic gastrostomy (PEG) 826, 827, 838
Percy Commission (1957) 850, 851
perforant pathway 233
perfusion MRI 435
periodic limb movement disorder (PLMD) 702
periodic limb movements in sleep (PLMS) 702
personal care/hygiene
aggression during assistance 761, 762
depression 113
problems, in FTD 348
personal development plans (PDPs) 856
personal history, in psychiatric history-taking 110–111

personality
age-related changes 495
assessment tests 392
changes, cognitive assessment 129–130
premorbid, in psychotic disorders 601,
in psychiatric history-taking 111
personality disorders 601, 649–654,
655–661
aetiology 649–650
epidemiology 649–650
psychosocial factors 650
ageing process altering pathology 656–657
antipsychotic drugs 604, 605

see also

borderline personality disorder (BPD)
classification 611, 649, 651, 655, 657
DSM-IV 107, 649, 655, 657
ICD-10 106
Cluster B (‘high-energy’) 651, 652
Cluster C (‘low-energy’) 651
cognitive distortions in 650
comorbidity 651, 655, 657
diagnosis and identification 655
decline with age 652
definition 649
depression with 498, 651–652, 655
see also DSM-IV, Axis I disorders
diagnostic criteria 656
dialectical behaviour therapy 546, 658
differential diagnosis 657
diagnostic procedures 651–652, 655
drug interactions 653
epidemiology 651–652, 655
summary 652
geriatric variants 652
histrionic 643, 649
impact on psychotherapy 658–659
importance in older people 649
long-term care (US) 793
management approaches 658
mature and immature types 656
obsessional 632
in offenders 696
paranoid see paranoid personality disorder
prognosis 652
stability/change over life span 656
suicidal behaviour 560

see also psychological therapy
personality styles, somatoform presentation 638

personality traits
adaptive and maladaptive 649
AD risk 273
context of expression 649
major, five-factor model (FFM) 656
suicidal behaviour 560

temporal stability 656–657
personal safety, dementia patients 413
person-centred care 813
Alzheimer’s disease 325
at care homes 79, 80
Dementia Care Mapping (DCM) 157, 159
at home, dementia patients 812
long-term care focusing on 159
person-centred ethics 768–769
person-centredness 768
personhood 742
ethics and 768–769
pesticides, suicide in China 739
pet therapy, in AD management 325
PGRN gene 348
prevalence 620
classification 612
chronic illness
physical symptoms
due to psychological trauma 636, 637
unexplained see ‘medically unexplained
symptoms’
physicians, primary care
private psychiatrists’ relationship (US) 781
see also general practitioners (GPs)
Pick, Arnold 348
Pick’s disease 348
4 Pillars of Alzheimer’s Prevention 424
pineal gland, age-related changes 48, 700
pterygoid plate
pituitary gland
anterior, age-related hormone changes
45–47
posterior, secreted substances 47–48
plantar reflex (Babinski sign) 121
plasma proteins, drug binding 56
plasticity
neuronal 36
synaptic see synaptic plasticity
platelets
APP fragments 300
in depression 470
dysfunction 470
membrane fluidity (PMF) 300
POCD see postoperative cognitive dysfunction (POCD)
polyarteritis nodosa, investigations 124
polyneuritis nodosa, investigations 124
polymyalgia rheumatica, investigations 124
polyphtalmy
58–59, 680
depression and 509, 511
minimization, anxiety treatment
guidelines 629
polysomnography (PSG) 127, 701
poly-substance misuse 681–682
Poor Law (UK) 745
population sizes
trends 83
see also demographics and ageing
posterior cingulate cortex 29, 30
in AD 29
Postgraduate Medical Education and Training Board (PMETB) 854, 855
post-hip fracture delirium see hip fracture
postoperative cognitive dysfunction (POCD)
818–821
definition 818, 819–820
hypoxaemia and hypotension role 818, 820
incidence at one week/three months 821
ISPOCD data 818, 819–820
as new disease vs unmasking of latent
problem 821
postoperative delirium see delirium
post-stroke depression see stroke, depression
after
post-traumatic stress disorder (PTSD)
641–642
bipolar disorder co-morbidity 577
chronic 641
classification 612, 640, 641
clinical features 641
delayed-onset 641
diagnosis and symptoms 614
differential diagnosis 640, 641–642
prevalence 620, 641
treatment 642
benzodiazepines 626
SSRIs 628
postural hypotension see orthostatic
hypotension
potentially reversible causes of dementia
(PrD) 383
see also reversible dementias
pout reflex 133
poverty 745
depression aetiology 618
practice nurses, depression management in
ethnic groups 521, 522
Prader–Willi syndrome 691
pramipexole, depression in Parkinson’s
disease 475
praxis
Alzheimer’s disease 227
assessment 132
prazosin, PTSD 642
Preadmission Screening and Annual Resident Reviews (PASARR) 792–793
precuneus, deactivation (fMRI) for memory encoding 439, 440
predementia
abnormal myo-inositol levels 282
identification by staging scales 162
markers 300
testing for/tn, ethics of 410
preferred priorities of care (end-of-life) 840–841
prefrontal cortex
in AD 29
age-related increased activation 29, 439
deterioration in normal ageing 29
earlier/faster ageing of 62
episodic memory 37
executive function 132
fMRI activity, memory function 439
ventromedial, hypoactivation, in depression 492
prejudice 743
premature ageing 51–52
pre-mild cognitive impairment
Clinical Dementia Rating scale 172
see also subjective cognitive impairment (SCI)
pretraining, memory training 398
prevalence, definition 207
prevention of mental disorders 844–849
definition 845
identifying target groups for interventions 847
indicated 845, 846
reasons for importance 844
selective 845–846
universal 845
see also individual disorders
Prevention of Suicide in Primary Care
Elderly: Collaborative Trial (PROSPECT) 525, 549, 562–563
primary care 750
Geriatric Depression Scale use 154
interface with psychiatry 552–553
somatic disorders 637
see also general practitioners (GPs)
Primary Care Groups (PCGs) 747
primary care homes 760
Primary Care Trusts (PCTs) 747
primary progressive aphasia (PPA) 113
PRIME-MD 497
primitive reflexes 133
prion diseases 108, 372–377
myoclonus 133
see also Creutzfeldt–Jakob disease (CID); other specific diseases
prion protein
aggregation (nucleation) 377
cellular (PrP*) 372
in CID (PrPSc–30) 373
conversion process 372
gene see PRNP gene
pathological (PrP*) 372, 375, 377
prion theory 372
prion(s)
elderly offenders 697
indeterminate sentences 851
prisoners 697
elderly, age of 694
prisoners of war (POWs), PTSD 641
private care (in UK) 749, 750, 751
private care homes 760
Private Finance Initiative (PFI) 747–748
private hospitals see private psychiatric hospitals (US)
private practice (US) 777–784
as a business 778–779
description 777
diagnostic services/evaluation 780, 781
educational/directive assistance provided 780–781
factors affecting patient/customer satisfaction 778–779
family involvement in care 781
geographical influences 778
HGPS and LGPS 779
history-taking and records 780
hospital admissions 782–783
increasing number of older patients 779
in-hospital treatment 783
initial contact with patient 780
inpatient hospital treatment 782
see also private psychiatric hospitals (US)
office planning and design 779–780
post-hospital treatment 783
professional organizations 782
psychiatrists 783
relationships with other physicians 783
relationships with other psychiatrists 781–782
relationships with other professionals 782
relations with hospitals 782
workload and incomes 779
range of services 780–781
referral to 778, 780
transport to and mobility issues 780
treatment options 783
continued interest/care 781
coordinated treatment plan 780
in-hospital treatment 783
psychopharmacologic therapy 780
private practitioners, definition 777
private psychiatric hospitals (US) 783, 796–802
admission patterns 799
description and services provided 796
discharge diagnosis 800
disorders treated 796, 800
inpatient treatment 782, 796–798
group therapy 798
length of stay 798–799
medical co-morbidity management 797
multidisciplinary team 797
multi-sensory behavioural therapy 798
neuropsychologist’s role 797–798
occupational therapist role 797
patient population 798
social worker role 797
specialised dementia units 796–797
inpatient units
adaptations used 796
structure and design 796
partial hospital programmes 799–801
example 801
PRNP gene 372, 377
codon 129 polymorphism 373, 374, 376
mutations in fatal familial insomnia 376
mutations in genetic CJD 375
P102L mutation 376
see also prion protein
pro-BACE1 290
problem-solving therapy (PST) 545
private psychiatric hospitals 799
procedural memory, training 326
professional relationships, private psychiatrists and 781–782
propenil 51–52
prion theory 372
progranulin 353
gene (PGRN) see PGRN gene
progressive non-fluent aphasia (PNFA) 348
brain imaging 30, 350
clinical presentation 349
progressive supranuclear palsy (PSP) 349
observation/assessment 130
supranuclear gaze 133
propranolol 57–58, 629
propofol 199
pronator drift 121
proxy ratings, quality of life (QoL) 133, 227
proverb interpretation 133, 227
proline-directed protein kinases (PDPKs) 446, 447
progeria 122
progestogen therapy 1970–1970 593
psychiatric consultation, collaboration with 8
psychiatric consultation, indications in hospital 510
psychiatric consultation, liaison with medical/surgical teams 552–553
psychiatric consultation, liaison with medical/surgical teams (primary care interface with) 552–553
psychometric testing 135
psychotic disturbances, in elderly, ICD-10 see psychiatric consultation, indications in hospital 510
psychotic disturbances, in elderly, ICD-10 see psychiatric consultation, indications in hospital 510
psychotic disorders 602
psychotic disorders (late-life) 591–608
psychotic disorders, in elderly offenders 697
psychotic disorders, in elderly offenders 697
psychotic disorders, in in-patient treatment and 783 see also geriatric psychiatrists
psychotic disorders, in long-term care in US 791, 793
psychotic disorders, in long-term care in US 791, 793
psychotropic drugs; individual drug groups 780
psychotropic drugs; individual drug groups 780
psychotropism 302
psychotropism 302
psychotropic drugs; protein-misfolding disorders 377
psychotropic drugs; protein-misfolding disorders 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
psychotropic drugs; protein-misfolding disorders (PMCA) 377
quality of life (QoL) 70, 183
quality adjusted life years (QALY) 94,
quality measures (QMs) 793–794
QRS complex, prolonged, tricyclic
QOL-AD measure 187, 188, 189
see QoL
qigong exercise 406
pursuit eye movements 133
pupils, examination 120
public health
psychotropic drugs
adverse outcome potential 795
cardiac effects 125, 126
g eriatric psychiatrist role in long-term
care in US 790–791
monitoring 126–127
over-prescribing 100
reviews by psychiatrist in long-term care 794–795
see also drug(s); psychopharmacological
drugs; individual drug groups
public health
dementia/cognitive function decline
impact 66, 207
education, on depression awareness 526
mental illness challenges 717, 724
prevention of disorders 845
see also prevention of mental disorders
suicide prevention strategies 561
Public–Private Partnership (PPP) 748
Public Safety, Mental Health Act 2007 and
Public–Private Partnership (PPP) 748
public safety, Mental Health Act 2007 and
Public–Private Partnership (PPP) 748
pulmonary embolism, ECT and 531
public health
dementia/cognitive function decline
impact 66, 207
education, on depression awareness 526
mental illness challenges 717, 724
prevention of disorders 845
see also prevention of mental disorders
suicide prevention strategies 561
Public–Private Partnership (PPP) 748
public safety, Mental Health Act 2007 and
pulmonary embolism, ECT and 531
pulvarin sign, variant CJD 125
pupils, examination 120
pursuit eye movements 133
qigong exercise 406
QoL see quality of life (QoL)
QOL-AD measure 187, 188, 189
QRS complex, prolonged, tricyclic
antidepressants causing 627
quality adjusted life years (QALY) 94,
criticism 176, 186
quality measures (QMs) 793–794
quality of care
care homes 79
Dementia Care Mapping (DCM)
evaluation 158
improvement by Dementia Care Mapping (DCM) 159
quality of life (QoL) 70, 183
in care homes 79
definitions and conceptualizations 183
evaluation/monitoring of health outcomes by 183, 184
as goal of care 410, 413
health-related see health-related quality of
dlife (HRQoL)
measurement 184
methods 185–186
in older age (instruments for) 186–187
see also quality of life (QoL) measures
subjective and objective dimensions 184
quality of life assessment schedule (QoLAS) 92
quality of life (QoL) measures 183–192, 185
dementia-specific 187–188, 189
direct observational tools 185
domains and variables involved 184
generic, for older people 186–187
generic vs disease-specific 185
in health 184
in mental illness 187
proxy ratings 185
selection 188–189
self-assessment scales 185
subjective and objective dimensions 184
utility assessments (cost-effectiveness) 186
validity and reliability 184–185
variation in scales 184
Quality of Well-Being (QWB) 179, 180
self-administered (QWB-SA) 179, 180
‘Question Asking Readings’ 325
quetiapine
Alzheimer’s disease 314
bipolar disorder 582
dosage and adverse effects 313
Lewy body dementia 369
psychotic disorders 605
quinacrine, in CJD 376
race see ethnic groups
radiology 124
barium studies 124
Ramón y Cajal, S. 331–332
rapid cycling 474
classification 458
rapid eye movement sleep behaviour
disorder (RSBD; RBD) 702
rating scales 141–144
for case finding 142, 143
cut-off scores 142, 143
delivery methods 142
development 141–142
for diagnosis 143
reliability 142
scores 142
for screening 142, 143
selection 143
types/uses 143
validity 142
REACH I 418
REACH II 418
reactive nitrogen species, overproduction in
AD 292
reactive oxygen species
DNA damage 53
overproduction, in AD 292
reading difficulties, Alzheimer’s disease 227
semantic dementia 349
testing 132, 136
reality orientation 326
receptive dysphasia 113
recognition memory, assessment 390
Record of Independent Living (RIL) 179,
reliability
Clinical Dementia Rating (CDR) 170,
Dementia Care Mapping (DCM) 158–159
recruitment of geriatric psychiatrists, in US 858
‘reduced reserves’ in old age 117
realin 293
re-feeding syndrome 826
regeneration of ageing brain 42–44, 333
see also neurogenesis
regenerative medicine
in AD 331
advanced therapies 334–338
clinical trial design 337
diseases appropriate for 337
drugs approved (FDA) 337–338
historical background 330–331
in Huntington’s disease 331
in Parkinson’s disease 331
see also gene therapy; neural stem cells (NSCs); neural transplantation
regenerative sprouting 42, 43
Regional Health Authorities (RHAs) 747
regulated intramembrane proteolysis (RIP) 289
rehabilitation 810–816
alcohol abuse 667
assessments for 811
attitudes to 814
definition 810
developing themes in 813–814
drug misuse 683
funding issues 812, 813
goals 810, 811, 813
long stay care and 812–813
neurorehabilitation, in dementia 813
NHS continuing care focus on 760
people and facilities aiding 811–812
person-centred care 813
planning 811
principles (in psychiatric disorders) 810–812, 814
prognosis-based plan 811
special problems with psychiatric
disorders 810
rehousing, psychotic disorders 606
rejection, fears of 709
relationships
depression impact on 546
doctor–patient see doctor–patient
relationship
family see families
pre-bereavement 555, 556
professional 781–782
quality
Dementia Care Mapping evaluating 158
disability affecting, rehabilitation and 811
pre-bereavement 555–556
spousal and well-being 464
supportive see supportive relationships
therapeutic 659
relaxation techniques 406
SUBJECT INDEX 903
reelin 293
’reduced reserves’ in old age 117
realin 293
re-feeding syndrome 826
regeneration of ageing brain 42–44, 333
see also neurogenesis
regenerative medicine
in AD 331
advanced therapies 334–338
clinical trial design 337
diseases appropriate for 337
drugs approved (FDA) 337–338
historical background 330–331
in Huntington’s disease 331
in Parkinson’s disease 331
see also gene therapy; neural stem cells (NSCs); neural transplantation
regenerative sprouting 42, 43
Regional Health Authorities (RHAs) 747
regulated intramembrane proteolysis (RIP) 289
rehabilitation 810–816
alcohol abuse 667
assessments for 811
attitudes to 814
definition 810
developing themes in 813–814
drug misuse 683
funding issues 812, 813
goals 810, 811, 813
long stay care and 812–813
neurorehabilitation, in dementia 813
NHS continuing care focus on 760
people and facilities aiding 811–812
person-centred care 813
planning 811
principles (in psychiatric disorders) 810–812, 814
prognosis-based plan 811
special problems with psychiatric
disorders 810
rehousing, psychotic disorders 606
rejection, fears of 709
relationships
depression impact on 546
doctor–patient see doctor–patient
relationship
family see families
pre-bereavement 555, 556
professional 781–782
quality
Dementia Care Mapping evaluating 158
disability affecting, rehabilitation and 811
pre-bereavement 555–556
spousal and well-being 464
supportive see supportive relationships
therapeutic 659
relaxation techniques 406
antipsychotic drugs 604–605
ECT 531
very late-onset 593, 597, 600
risk factors 597
symptoms 593
schizophrenia-like psychotic disorder 98
scrappy 376
self-neglect 122
self-directed care 98
SELF-CARE D rating scale 142
self-directed care 814
self-harm, in general hospitals 806
self-neglect 122
self-rating scales 142
self-reported functioning 66
semantic dementia (SD) 348
brain functional changes 30
clinical presentation 349–350
speech in 113
semantic memory 131, 390, 397
assessments 131, 390
impairment 131–132
senile dementia, concept formation (historical) 4–5
senile plaques 36
senile psychoses (involutional psychoses) 5
‘senile squalor’ syndrome 632
‘senility’, historical use of term 203
Seniors Aging Gracefully Everyday (SAGE) programme 801
sensation, testing 121
sense of purpose 98
sensorimotor function 289
sensory distortions, in Mental State Examination (MSE) 115
sensory losses/changes 289
sensory deprivation 797
sex differences
see also gender
SEXUAL DYSFUNCTION 706–710
Severe Cognitive Impairment Scale 157
Severe Head Injury Scale 157
seizures 690
during ECT 532
selection pressure 51
selective attention
Down syndrome 283
testing 389
selective serotonin reuptake inhibitors (SSRIs) 537–538
advantages 538
Alzheimer’s disease 308–309
anxiety/anxiety disorders 628, 629
efficacy 628
guidelines for use 628
depression/depressive disorders 537–538
in China 739
response rates 538
treatment-resistant depression 539
depression in Parkinson’s disease 475
drug interactions 537, 538
dysthymia 498
effect on vascular disease 470
frontotemporal dementia syndrome 353
initiation 552
lithium with 539
OCD treatment 633–634
in Parkinson’s disease 475
personality disorders 659
pharmacokinetics 537
PTSD 642
side effects 538, 628
suicidal risk reduction 563
self-affirming interventions 326
SELF-CARE D rating scale 142
self-directed care 814
self harm, in general hospitals 806
self-neglect 122
sexual activity
consent, and dementia 75
frequency in older people 74
illness affecting 74, 707
problems in men/women 74, 707
see also sexual disorders
sexual desire, reduced 707
in men 708
in women 708
sexual disorders 706–710
drug-induced 707
male 708
in physical illnesses 74, 707
women 708–709
sexual experimentation 707
sexual history 709
sexual intercourse see sexual activity
sexuality and ageing 74–77, 706–707
consent issues and dementia 75
HIV infection 76
homophobia and heterosexism 75–76
illness and medication effects 74, 707
negative societal attitudes 76
older people as post sexual 709
see also lesbian, gay and bisexual (LGB) people
sexually transmitted disease (STD), elderly prisoners 697
sexual needs, of older people 74, 706
sexual offences 694, 697, 698
sexual problems/difficulties 706, 707
common, in couples 709
sexual response, age-related changes 706–707
consent and dementia 75
illness affecting 74, 707
problems in men/women 74, 707
see also sexual disorders
silence 707
sexual arousal disorder, in women 708
sexual behaviour, inappropriate 75
in care homes 697
in dementia 694, 697
sexual desire, reduced 707
in men 708
in women 708
sexual disorders 706–710
drug-induced 707
male 708
in physical illnesses 74, 707
women 708–709
sexual experimentation 707
sexual history 709
sexual intercourse see sexual activity
sexuality and ageing 74–77, 706–707
consent issues and dementia 75
HIV infection 76
homophobia and heterosexism 75–76
illness and medication effects 74, 707
negative societal attitudes 76
older people as post sexual 709
see also lesbian, gay and bisexual (LGB) people
sexually transmitted disease (STD), elderly prisoners 697
sexual needs, of older people 74, 706
sexual offences 694, 697, 698
sexual problems/difficulties 706, 707
common, in couples 709
sexual response, age-related changes 706–707
consent and dementia 75
illness affecting 74, 707
problems in men/women 74, 707
see also sexual disorders
signalling
intracellular calcium, abnormal in AD 292, 307
neuregic stem cell niche 333
tau phosphorylation regulation 292, 293
sildenafil 708
silent infarcts 344, 578
simple attention span, testing 389
simultanagnosia 132
Sinclair, Sir John 4
Single Assessment Process 753
single photon emission computed tomography (SPECT) 28, 125, 257–258
<table>
<thead>
<tr>
<th>Subject</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>memory enhancement</td>
<td>407</td>
</tr>
<tr>
<td>reduced rates of mental disorder</td>
<td>98</td>
</tr>
<tr>
<td>see also religion</td>
<td></td>
</tr>
<tr>
<td>spiritual needs</td>
<td></td>
</tr>
<tr>
<td>of mental health service staff</td>
<td>743</td>
</tr>
<tr>
<td>of service users (patients)</td>
<td>742–743</td>
</tr>
<tr>
<td>staff supporting</td>
<td>742–743</td>
</tr>
<tr>
<td>splitting (of) treatment team (by patient)</td>
<td>658</td>
</tr>
<tr>
<td>spousal bereavement</td>
<td>498, 499</td>
</tr>
<tr>
<td>cause of depression</td>
<td>520</td>
</tr>
<tr>
<td>spousal negativity</td>
<td>464</td>
</tr>
<tr>
<td>spousal relationship, well-being relationship</td>
<td>464</td>
</tr>
<tr>
<td>spouses, as caregivers</td>
<td>829, 830</td>
</tr>
<tr>
<td>mental health outcomes</td>
<td>831–832</td>
</tr>
<tr>
<td>placement of spouse in nursing home</td>
<td></td>
</tr>
<tr>
<td>staff (mental health service)</td>
<td>848</td>
</tr>
<tr>
<td>Institute of Medicine (IOM) report</td>
<td>858</td>
</tr>
<tr>
<td>spiritual needs</td>
<td>743</td>
</tr>
<tr>
<td>spiritual support for patients</td>
<td>743</td>
</tr>
<tr>
<td>workforce gap in US</td>
<td>774</td>
</tr>
<tr>
<td>staging of dementia</td>
<td></td>
</tr>
<tr>
<td>see dementia, staging</td>
<td>498</td>
</tr>
<tr>
<td>STAR-D</td>
<td></td>
</tr>
<tr>
<td>statins, AD prevention</td>
<td>274</td>
</tr>
<tr>
<td>statistical parametric mapping (SPM)</td>
<td>29</td>
</tr>
<tr>
<td>stem cell niche</td>
<td>332</td>
</tr>
<tr>
<td>see also neurogenic stem cell niche</td>
<td></td>
</tr>
<tr>
<td>stem cells</td>
<td>332</td>
</tr>
<tr>
<td>embryonic</td>
<td>330, 334, 335</td>
</tr>
<tr>
<td>neural see neural stem cells (NSCs)</td>
<td></td>
</tr>
<tr>
<td>neuronal</td>
<td>43</td>
</tr>
<tr>
<td>stepped-care models, prevention of depression</td>
<td>846</td>
</tr>
<tr>
<td>stigma</td>
<td></td>
</tr>
<tr>
<td>dementia</td>
<td>719</td>
</tr>
<tr>
<td>depression</td>
<td>519, 521, 524, 526</td>
</tr>
<tr>
<td>drug misuse</td>
<td>682</td>
</tr>
<tr>
<td>personality disorders</td>
<td>656</td>
</tr>
<tr>
<td>Stone, Michael</td>
<td>850</td>
</tr>
<tr>
<td>Strategic Health Authorities (SHAs)</td>
<td>747</td>
</tr>
<tr>
<td>Strategic Health Authorities (SHAs)</td>
<td></td>
</tr>
<tr>
<td>stress</td>
<td></td>
</tr>
<tr>
<td>adjustment disorder</td>
<td>499</td>
</tr>
<tr>
<td>anxiety treatment indication</td>
<td>624</td>
</tr>
<tr>
<td>caregivers see caregivers/carers; family caregivers</td>
<td></td>
</tr>
<tr>
<td>coping with, ability</td>
<td>465</td>
</tr>
<tr>
<td>see also coping abilities</td>
<td></td>
</tr>
<tr>
<td>depression triggered by</td>
<td>509</td>
</tr>
<tr>
<td>perceived, by caregivers</td>
<td>415, 417</td>
</tr>
<tr>
<td>progressively lowered threshold in AD</td>
<td>324</td>
</tr>
<tr>
<td>severe, reactions to</td>
<td>612</td>
</tr>
<tr>
<td>see also acute stress reaction</td>
<td></td>
</tr>
<tr>
<td>suicide prevention</td>
<td>562</td>
</tr>
<tr>
<td>‘stressed synapses’</td>
<td>38</td>
</tr>
<tr>
<td>stressful life events</td>
<td>49</td>
</tr>
<tr>
<td>stressors</td>
<td></td>
</tr>
<tr>
<td>alcohol abuse and</td>
<td>666</td>
</tr>
<tr>
<td>depression associated</td>
<td>566, 618</td>
</tr>
<tr>
<td>physical ill-health and</td>
<td>618–619</td>
</tr>
<tr>
<td>psychosocial, personality disorders development</td>
<td>657</td>
</tr>
<tr>
<td>suicide risk and prevention</td>
<td>562</td>
</tr>
<tr>
<td>stress process model</td>
<td>415</td>
</tr>
<tr>
<td>stress reduction techniques</td>
<td>406</td>
</tr>
<tr>
<td>stroke</td>
<td></td>
</tr>
<tr>
<td>alcohol use and</td>
<td>675</td>
</tr>
<tr>
<td>dementia</td>
<td>342</td>
</tr>
<tr>
<td>clinical course</td>
<td>343</td>
</tr>
<tr>
<td>epidemiology</td>
<td>343–344</td>
</tr>
<tr>
<td>IQCODE prediction of</td>
<td>149</td>
</tr>
<tr>
<td>progressive lowering threshold in AD</td>
<td></td>
</tr>
<tr>
<td>time of onset</td>
<td>343</td>
</tr>
<tr>
<td>see also vascular dementia (VaD)</td>
<td></td>
</tr>
<tr>
<td>depression after</td>
<td>468, 515–517, 552, 567, 569, 619, 719</td>
</tr>
<tr>
<td>diagnosis</td>
<td>515</td>
</tr>
<tr>
<td>left-sided vs right-sided stroke</td>
<td>567</td>
</tr>
<tr>
<td>prevalence</td>
<td>515</td>
</tr>
<tr>
<td>prevention</td>
<td>516</td>
</tr>
<tr>
<td>treatment</td>
<td>516</td>
</tr>
<tr>
<td>depression as risk factor of</td>
<td>469, 567</td>
</tr>
<tr>
<td>ECT after</td>
<td>531</td>
</tr>
<tr>
<td>lesion location, depression association</td>
<td>515, 567</td>
</tr>
<tr>
<td>mania after</td>
<td>574</td>
</tr>
<tr>
<td>mania precipitated by</td>
<td>574</td>
</tr>
<tr>
<td>meningovascular neurosyphilis vs</td>
<td>428</td>
</tr>
<tr>
<td>neurogenesis after</td>
<td>334</td>
</tr>
<tr>
<td>prevalence, in China</td>
<td>737</td>
</tr>
<tr>
<td>prevention</td>
<td>345</td>
</tr>
<tr>
<td>risk factors</td>
<td>344</td>
</tr>
<tr>
<td>depression</td>
<td>469, 567</td>
</tr>
<tr>
<td>risperidone causing</td>
<td>58</td>
</tr>
<tr>
<td>see also cerebrovascular disease</td>
<td></td>
</tr>
<tr>
<td>Stroop color-word interference</td>
<td>491</td>
</tr>
<tr>
<td>Stroop Color Word test</td>
<td>21, 392, 491</td>
</tr>
<tr>
<td>structural changes (brain)</td>
<td>17, 36</td>
</tr>
<tr>
<td>macrostructural</td>
<td>18</td>
</tr>
<tr>
<td>Structured Interview for Disorders of</td>
<td></td>
</tr>
<tr>
<td>Personality scale (SIDP-R)</td>
<td>651, 655</td>
</tr>
<tr>
<td>structure–function correlations, MRI,</td>
<td></td>
</tr>
<tr>
<td>normal ageing</td>
<td>17</td>
</tr>
<tr>
<td>Study of Health and Retirement in Europe</td>
<td></td>
</tr>
<tr>
<td>see SHARE study</td>
<td></td>
</tr>
<tr>
<td>subcortical–cortical pathway disconnection</td>
<td>344</td>
</tr>
<tr>
<td>subcortical dementia</td>
<td>233</td>
</tr>
<tr>
<td>subcortical hyperintensities, mania</td>
<td>574</td>
</tr>
<tr>
<td>subcortical lesions, alcoholic dementia</td>
<td>378</td>
</tr>
<tr>
<td>subcortical syndromes, observation in</td>
<td>130</td>
</tr>
<tr>
<td>subdural haematoma (SDH)</td>
<td>384</td>
</tr>
<tr>
<td>reversible dementia</td>
<td>385, 386</td>
</tr>
<tr>
<td>subgranule layer (SGL) of dentate gyrus,</td>
<td></td>
</tr>
<tr>
<td>neurogenesis</td>
<td>291, 332</td>
</tr>
<tr>
<td>subjective cognitive impairment (SCI)</td>
<td>164</td>
</tr>
<tr>
<td>Functional Assessment Staging (FAST)</td>
<td>167</td>
</tr>
<tr>
<td>GDS scale</td>
<td>163, 164</td>
</tr>
<tr>
<td>time course</td>
<td>163</td>
</tr>
<tr>
<td>see also pre-mild cognitive impairment</td>
<td></td>
</tr>
<tr>
<td>substance abuse</td>
<td>679</td>
</tr>
<tr>
<td>by abusers of the elderly</td>
<td>836</td>
</tr>
<tr>
<td>bipolar disorder co-morbidity</td>
<td>577</td>
</tr>
<tr>
<td>definitions</td>
<td>679, 680</td>
</tr>
<tr>
<td>mood disorders due to</td>
<td>566</td>
</tr>
<tr>
<td>see also alcohol abuse; drug misuse</td>
<td></td>
</tr>
</tbody>
</table>

SUBJECT INDEX

907

Substance Abuse and Mental Health Services Administration (SAMHSA) 177, 774
substances of abuse 679
dementia associated 380
substantia nigra, mitochondrial mutations 53
substituted judgement standard 411
subsyndromal depression (SSD) 498, 566
subventricular zone (SVZ) 334
changes, olfaction impairment 334
neurogenesis 291, 332
thickening in Huntington’s disease 334
thinning in Parkinson’s disease 334
successful ageing 70–73
biomedical theories 71
definition 70, 72
good self-rated health correlation 71, 72
lay definitions/views 70, 71–72
multidimensional models 70
parameters, associations between pairs 72
good self-rated health correlation 71, 72
lay definitions/views 70, 71–72
multidimensional models 70
parameters, associations between pairs 72
psychological models/resources 70–71
Ryff’s theoretical model 71
see also normal ageing
suicidal behaviour 559–564
Alzheimer’s disease and 560, 561, 806
deterrents 562
hospitalization for 562
hospitalization outcomes 563
management 562–563
risk factors 559–561
adulthood factors 560
biological factors 561
demographic factors 559
early life factors 559–560
late life factors 560–561
physical health/disability 560–561
previous suicidal behaviour 560
psychopathology 560
psychosocial factors 561
suicidal ideation 563
in depression 497, 512, 560
prevalence 559
religious views affecting 742
suicide
acceptability, different ethnic groups 714–715
after homicide 695
attempted, decline in rates with age 559
depression see depression (geriatric), suicide
methods, China 739
prevention strategies 561–563
indicated prevention 562–563
selective prevention 561–562
universal prevention 561
rates 559, 806
China 739–740
depression, in South Asia 731
religious views 742
risk 559
in depression 500
reduced with spiritual beliefs 741
risk assessment 562
‘sundowning’ 703
TAR DNA-binding protein 43 (TDP-43) 348, 351, 352

task simplification 326
tau 287, 292, 351
anaesthetic effect 822
antibodies 253
conditional transgenic mouse model 253, 254
FTD variants with/without 351–353
haplootype H1 and H2 282
hyperphosphorylation 240, 252, 287, 291–292, 352
GSK3 association 292
inclusions 252
increased in AD 300
isoforms 252
mutations 254
frontotemporal dementia 127
normal ageing and MCI 295
phosphorylation
genes regulating 282
signalling cascade regulating 293
sites, and enzymes 292
see also neurofiob bilateral tangles
tau kinase, inhibitors 309
tauopathies 108, 352
transgenic mouse models 252–253
see also frontotemporal dementia (FTD) syndromes
TCAs see tricyclic antidepressants
TDP-43 348, 351, 352
technetium-99m labelled ethylcysteinate dimer (99mTc-ECD) 257
technetium-99m labelled hexamethylpropyleneamine (99mTc-HMPAO) 257
Tele-Check 562
Teke-Help 561–562
telomere sequences, shortening 52
temazepam, pharmacodynamics 58
temporal arteries 124
temporal lobe atrophy, in MCI vs AD 266, 267
Temporal Orientation Test (TOT) 389
temporoparietal cortex, in AD 29
Test of Everyday Attention 137
testosterone, age-related changes in levels 46–706, 708
in women 706
test-retest reliability 142
MMSE 145
‘tet-off system’ models 254
theory of mind 349
therapeutic alliance, personality disorders 659
therapeutic drug monitoring 126, 537
therapeutic nihilism 525
therapeutic relationship, personality disorders 659
thermoregulation, impairment 58
thiamine 379
deficiency 378, 379
replacement 826
thiazide diuretics, lithium interactions 581
thioridazine, in Alzheimer’s disease 314
thought diary 544, 545
thyroid autoantibodies 47
thyroid dysfunction, reversible dementia 384
thyroid function testing (TFT) 124
thyroid hormones 384
age-related changes 47
thyroid-stimulating hormone (TSH) 47
thyrotrophin-releasing hormone (TRH) 47
thyroxine (T4) 47
TOR pathway 53, 54
‘total pain’ 839
total sleep time (TST) 701
Tourette’s syndrome 632
traditional healers 715

training
career choice 860
doctors 748
geriatric psychiatrists 814, 860–863
consensus curriculum 861
postgraduate schools 862
recent developments 860–861
geriatric psychiatrists in Canada 861, 862

geriatric psychiatrists in UK 8–9, 854–856, 860
advanced training 855
content, assessment and appraisal 862
continuing professional development 855–856
core training 855
development/growth as specialty 854
duration 854, 855
formative/summative assessments 862
lifelong learning 856
postgraduate education 854
postgraduate schools 862
undergraduate teaching 854

geriatric psychiatrists in US 857–859, 860, 861, 862
ACGME program requirements 857–858
funding for studies on 858
incentives 858
mentorship 858
liaison psychiatry 804–805
on nutrition 827
provision 860–861
see also education
tranquilizers
misuse 682
see also antipsychotic drugs; anxiolytics
transcranial magnetic stimulation (TMS) 37
repetitive see repetitive transcranial magnetic stimulation (rTMS)
transferrin
carbohydrate-deficient 667
decrease in AD 301
TfC2, as antemortem marker 301
transgenic mice see mouse models
transient ischaemic attack,risperidone causing 58

superoxide dismutase 282
superoxide dismutase 3 gene 53
Supervised Community Treatment (SCT) 852
support groups, family caregivers 418–419
supportive relationships 98, 464, 465
dementia patients in care homes 80
in mental disorders 98
see also social support

support network
activation difficulty in depression 464–465
patients of US private practice 781
see also social networks

support-orientated track, private psychiatric hospitals (US) 799

support services
family caregivers 418–419, 831–832
in rehabilitation 811

suprachiasmatic nucleus (SCN) 48, 300, 700

sleep disturbances in AD 703

supranuclear gaze 133

’surface dyslexia’ 349

’surgical teams, liaison with mental health teams see liaison psychiatry

surrogates, decision making 411, 412, 769
surveillance, dementia patients 413
swallowing reflex 764
Sydenham’s chorea 632

symptoms, non-specific, in older people 117

synaptic dysfunction, amyloid-related, in AD 437
synaptic failure, Aβ misfolding and oligomerization and 290–291

synaptic plasticity 42, 197
in AD 37
increased by exercise 406

synaptic redundancy 36

syndrome, concept 616

syndrome of inappropriate antidiuretic hormone (SIADH) 122, 123
α-synuclein 360

deposition, pathogenesis 363, 365
gene mutation, Parkinson’s disease 127
gene triplication 367
Lewy body dementia aetiology 363
α-synucleinopathies see Lewy body dementia spectrum

synucleinopathy, early, REM sleep behaviour disorder 702

syphilis
investigations 124, 428
neurosyphilis 384, 428
ocular 428
treatment 428

Systematic Treatment Enhanced Program for Bipolar Disorder (STEP-BD) 580, 583

systemic lupus erythematosus (SLE) 124

tabes dorsalis 428
tacrine 296, 304
tadalafil 708
Taiwan, depression prevalence 482–483

908 SUBJECT INDEX

in Alzheimer’s disease 227
challenging, in CBT 544
content and form 114
in Mental State Examination (MSE) 114
thought diary 544, 545
thyroid autoantibodies 47
thyroid dysfunction, reversible dementia 384
thyroid function testing (TFT) 124
thyroid hormones 384
age-related changes 47
thyroid-stimulating hormone (TSH) 47
thyrotrophin-releasing hormone (TRH) 47
thyroxine (T4) 47
TOR pathway 53, 54
‘total pain’ 839
total sleep time (TST) 701
Tourette’s syndrome 632

traditional healers 715

training
career choice 860
doctors 748
geriatric psychiatrists 814, 860–863
consensus curriculum 861
postgraduate schools 862
recent developments 860–861
geriatric psychiatrists in Canada 861, 862

geriatric psychiatrists in UK 8–9, 854–856, 860
advanced training 855
content, assessment and appraisal 862
continuing professional development 855–856
core training 855
development/growth as specialty 854
duration 854, 855
formative/summative assessments 862
lifelong learning 856
postgraduate education 854
postgraduate schools 862
undergraduate teaching 854

geriatric psychiatrists in US 857–859, 860, 861, 862
ACGME program requirements 857–858
funding for studies on 858
incentives 858
mentorship 858
liaison psychiatry 804–805
on nutrition 827
provision 860–861
see also education
tranquilizers
misuse 682
see also antipsychotic drugs; anxiolytics
transcranial magnetic stimulation (TMS) 37
repetitive see repetitive transcranial magnetic stimulation (rTMS)
transferrin
carbohydrate-deficient 667
decrease in AD 301
TfC2, as antemortem marker 301
transgenic mice see mouse models
transient ischaemic attack, risperidone causing 58
long stay care 812
mental health law see law (mental health) (UK)
net importer of doctors/psychiatrists 860
palliative care 838
Parkinson’s disease prevalence 473
population pyramids and changing distribution 84
psychogeriatric services see
psychogeriatric services (England)
psychotic disorder prevalence 597
south Asian people see south Asians in (UK)
training of psychiatrists see training
undergraduate teaching, psychiatry 854
under-nutrition 825
unexplained physical symptoms see
‘medically unexplained symptoms’
unipolar disorder 496
classification 458
Parkinson’s disease (PD) 474
see also depression (geriatric)
unmet needs model 324, 325
upper motor neurone lesion 121
urine
mid-stream (MSU) assessment 124
screening for drug misuse 682
US (United States of America)
access to psychological therapy 549
AD societies see Alzheimer’s disease societies (USA)
Alzheimer’s disease costs 421
Alzheimer’s disease prevalence 415, 421
complementary/alternative medicine usage trends 403
coping abilities and environmental factors 466
demographics and ageing 84, 100, 421, 772–773, 857
depression prevalence 480, 482, 483
eric mental health care 770–776
ageing and serious mental health
increase 774
concerns over availability 778
financing 770–772
future challenges 772–774
gap between research/practice and policy 774
health care reforms 772–773
home and community-based options 773–774
integrated mental and physical health care 773
long-term care see long-term care medical psychiatric inpatients see
medical psychiatric inpatient unit (US)
outpatient 777–784
private psychiatric hospitals see private psychiatric hospitals (US)
workforce gap 774
see also Medicaid (US); Medicare (US)
homicide rates 695
illicit drug misuse 681
long-term care in 790, 812
Lyme disease incidence 427
medical psychiatric inpatient unit see
medical psychiatric inpatient unit (US)
palliative care 838
population pyramids and changing distribution 84
psychiatric services in long-term care see
long-term care regulations for long-term care 792–795
self-directed care 814
syphilis incidence 428
training of geriatric psychiatrists see
training
tuberculosis incidence 426
utilitarianism 766, 851
vaginal dryness 706, 707, 708
validation therapy 326
validity
Clinical Dementia Rating (CDR) 170, 172
Dementia Care Mapping (DCM) 158
Geriatric Depression Scale (GDS) 152–153
Global Deterioration Scale (GDS) 165
IQCODE 149
MMSE 145–146
quality of life (QoL) measures 184–185
rating scales/instruments 142
valosin-containing protein (VCP) 353
valproate
acute mania 581
Alzheimer’s disease 320
bipolar disorder treatment 539
monitoring 126
pharmacokinetics 581
side effects 581
vardenafil 708
variant Creutzfeld–Jakob disease (CJD) 373, 375–376
pulvinar sign 125
vascular cognitive impairment 342, 343
vascular dementia (VaD) 342–347
Alzheimer’s disease with 203, 208, 345
causes 343
stroke 342, 343–344
white matter lesions 342, 344
classification 342–343
DSM-IV and ICD-10 106, 342
NINDS-AIREN criteria 342–343
cognitive impairment, personality disorders vs 657
diagnosis/screening 345
diagnostic criteria and definitions 342–343
epidemiology 343–344
learning disability with 689
magnetic resonance spectroscopy 451
pathogenesis 344
prevalence 719, 720
China 737
South Asia 719, 730
risk factors 344, 345
subcortical, memory impairment not main symptom 204
treatment 345–346

ubiquitin-positive inclusions, in FTD 352, 353
UCSD Performance-Based Skills Assessment (UPSA) 179, 181
UK 745–769
access to psychological therapy 7, 527, 549
Alzheimer’s disease prevalence 415
black Caribbean people see black Caribbean people (UK)
day hospitals 753–755
demographics and ageing 84, 524
depression in ethnic groups see ethnic groups
devolution, effect on health services 747, 749
health and social services development 745–748
1918–1939 745–746
history 745
market forces and competition 746–747, 749
NHS see National Health Service (NHS)
illicit drug misuse 681
learning disability prevalence 689
liaison psychiatry 803

tricyclic antidepressants 537, 627–628
tuberculomas 426
tremor 133
tricoferret 133
Treponema pallidum 428
tri-iodothyronine (T3) 47
‘triple jeopardy’ 518
‘triple jeopardy’ 518
trisomy 21 see Down syndrome
trophic support, for neuronal connections 42, 43
tuberculosis 426
tuberculosis 426–427
two-dimensional chemical shift correlated
MRS (2D-COSY) 451

transplantation, neural/stem cell see neural transplantation
transportation, to private psychiatric practices 870
tranylcypromine 628
trasina 405–406
traumatic brain injury (TBI), AD risk 272
traumatic events, PTSD after 641
trazodone
Alzheimer’s disease 319
anxiety/anxiety disorders 627–628
FTD syndromes 353
tremor 133
Treponema pallidum 428
tremor 133
tricuspid anticoagulants 537, 627–628
anticholinergic side effects 628
efficacy 627
guidelines for use 628
side effects 627–628
depression treatment 537
in Parkinson’s disease 475
limitations/advantages 537
older people as highest users 538
tri-iodothyronine (T3) 47
‘triple jeopardy’ 518
trisomy 21 see Down syndrome
trophic support, for neuronal connections 42, 43
tuberculomas 426
tuberculosis 426–427
two-dimensional chemical shift correlated
MRS (2D-COSY) 451
vascular depression 458, 460–461, 468, 496–497, 499, 619

cerebrovascular risk factors 468
diagnostic criteria 497
see also vascular disease

cerebrovascular disease hypothesis 487, 496–497, 578, 619

vascular disease 468–472, 487, 824
as AD risk factor 272–273, 723
depression (late-life) relationship
causation mechanisms 469–470
depression as risk factor 469, 497
depression complicating 468, 490, 496–497
in Parkinson’s disease 474
treatment 470
see also depression; vascular depression

suicidal behaviour risk factors 560
see also cerebrovascular disease

vasoactive drugs, in depression/vascular disease 470

vasopressin see arginine-vasopressin (AVP)

Venerable Disease Research Laboratory (VDRL) test 124, 428

venlafaxine
anxiety/anxiety disorders 628, 629
typical depression 497
depression in Parkinson’s disease 475
treatment-resistant depression 539
ventral lateral preoptic (VLPO) area 700
ventricular volume
dilatation, delusional disorder 601
schizophrenia 602
verbal fluency 131, 132
testing 131
Vermont Longitudinal Study 597
very late-onset schizophrenia-like psychosis (VLOSLP) see schizophrenia, very late-onset

very low-density lipoproteins receptor (VLDLR) 293

vesicular glutamate transporter (VGluT) 296

Veteran Health Administration (VHA) 423
video, experience of dementia patients in care homes 79
vigilance, testing 389–390
violence
fatal 694–695
non-fatal 695
in psychotic disorders 606–607
in REM sleep behaviour disorder 702
risk assessment 698
see also aggressive behaviour; offenders
‘virtual lesions’ 37

virtue theory 767
visual acuity, assessment 120
visual fields, assessment 120
visual hallucinations 114, 230, 295, 599
CJD 377
incidence/prevalences 597
Lewy body dementias 364, 365
management 368–369
Parkinson’s disease (PD) 600

visual impairment
in learning disability 691
management in AD 327
psychotic disorder assessment 602
Visual Object and Space Perception Battery 136
visual perception, assessment 138

visuospatial deficits
Alzheimer’s disease 39, 227, 393
depression 394
detection 392
in MCI and mild AD 39
visuospatial function, assessment 132, 138, 392
vitamin B6, supplements 404
vitamin B12
deficiency 123, 384
dementia aetiology 723
replacement 826
supplements in AD 308, 404, 407
vitamin D, deficiency 826
vitamin E
AD decline reduction 308
AD prevention 275
volume of distribution (V) 55–56, 537
alcohol effects and 665
don Economo neurons, loss 351
voting in dementia, ethics 412
voxel-based morphometry (VBM), in depression 489, 490

vulnerability
of caregivers, to disease 831
to elder abuse 836
of elderly, to exploitation 614
feelings of, in elderly people 614
increase with age 599
in personality disorder patients 659
vulnerability–diathesis model 543

wake after sleep onset (WASO) 701
wandering, in Alzheimer’s disease 230

warfarin, pharmacodynamics 58

Warren, Earl 850, 853
‘wear and tear’ view 3

Wechsler Adult Intelligence Scale III (WAIS-IV) 390
Wechsler Memory Scale (WMS-III) 136, 138
weight
gain 824–825
loss in dementia 826
weight bearing, maintaining ability 763
well-being 183
Dementia Care Mapping (DCM) evaluation 158, 159
depression outcome 505
diverse social networks and 466
spousal relationship and 464
see also quality of life (QoL)
Werner syndrome (WS) 52
Wernicke–Korsakoff syndrome 378, 826

white matter changes
normal ageing 18
shrinkage, normal ageing 18
white matter hyperintensities (WMHIs) 22, 23
late-life depression and 468, 490
periventricular 490
quantification 490
white matter lesions (WMLs)
cognitive decline due to 344
ischaemic 342, 344, 468, 490
late-life depression and 468, 470, 490
pathogenesis and risk factors 344
subcortical 344
vascular dementia due to 342, 344
whole of life approach, ageing 561
widows/widowers, selective prevention of mental disorders 845
‘widow-to-widow’ programmes 845
Wisconsin Card Sorting Test (WCST) 232, 392

women
age-related hormonal changes 706
coping abilities and resource deficits 466
prisoners 697
suicidal behaviour 559
word comprehension difficulties 349
word finding difficulties
Alzheimer’s disease 226
frontotemporal dementia 350
working memory 131
assessment 131, 390
deficits, normal aging 17
dorsolateral prefrontal cortex role 37
workplace-based assessments (WPBA) 855, 862

World Alzheimer Report 721, 722
world backwards test 145
World Health Organization (WHO) consensus statements on geriatric psychiatry 860, 861
depression syndrome diagnosis 679
revised working disability model 178
World Health Organization Quality of Life Group (WHOQOL) 184
World Psychiatric Association (WPA) 861

World War II
health and social services in UK before 745–746
PTSD in veterans 641
writing, assessment 132

WRN mutation 52
wwp-1 gene 53

YENPTY motif, APP 288
yoga, memory improvement 406, 407

zeitgebers 700, 701
zinc
levels in AD 301
supplement, effect in AD 301
zopiclone, insomnia treatment 701
Zung Self-Rating Depression Scale (SDS) 152